This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

Orchid: here for those who need us “4 most.

Annual report and fĳ inanc i al statements 2023–2024 | ORCHID CANCER APPEAL

ORCHID CANCER APPEAL | Annual report and fĳ inanc i al statements 2023–2024

ORCHID CANCER APPEAL inanc i al Annual report and fĳ statements 2023–2024

Board of Trustees

Mr D Badenoch

Mr W Cohen, Treasurer

Mr J Shedden (appointed 7 December 2023) Mr CS Osborne, Chair (resigned 14 April 2025) Mr B Ayres (resigned 14 April 2025)

Mr PG Bracher (resigned 14 April 2025) Mr M Bryan-Brown (appointed 4 December 2024, resigned 14 April 2025) Mr S Harris (resigned 14 April 2025) Mr M Kibblewhite (resigned 11 September 2024) Professor RTD Oliver (resigned 24 January 2025) Professor P Rajan (appointed 7 December 2023, resigned 13 April 2025) Dr J Reddy (appointed 4 December 2024, resigned 14 April 2025)

Chief Executive

Mr A Orhan

Independent Examiner

Moore Kingston Smith LLP 6th Floor, 9 Appold Street, London EC2A 2AP

Accountants

JS2 Limited

1 Crown Square, Woking, Surrey GU21 6HR

Legal advisors

Farrer & Co 66 Lincoln’s Inn Fields, London WC2A 3LH

Bankers

HSBC Plc 20 Electric Parade, George Lane, South Woodford, London E18 2LX

Registered O ffi ce 60 Gray’s Inn Road, London WC1X 8AQ

Tel 020 3745 7310 www.orchid-cancer.co.uk

Registered in England with the Charity Commission No.1080540

Company Limited by Guarantee Registered in England No. 3963360

Annual report and fĳ inanc i al statements 2023–2024 | ORCHID CANCER APPEAL

ORCHID CANCER APPEAL | Annual report and fĳ inanc i al statements 2023–2024

Welcome from Col i n Osborne MBE, Honorary Pres i dent

am pleased to share the signi fĳi cant strides our charity has made in the fĳi nancial year 2023-2024 in the fĳi ght against prostate, testicular and I penile cancers.

Orch i d was so Governance matters proud when, We were delighted to welcome two new Trustees out of over 500 during the year: Professor Prabhakar Rajan and Jerry appl i cat i ons, Shedden in December 2023. Mark Kibblewhite stepped our char i ty was down during the year, and I would like to recognise his tremendous contribution, including as an active announced as member of the Finance Committee. one of ten It was with great sadness that we heard in July of the w i nners of a death of former Trustee Lord Robert Fellowes, who had 2024 GSK served as Queen Elizabeth II’s private secretary. Lord Impact Award Fellowes’ steadfast commitment, wisdom, and leadership were instrumental in advancing our mission to fĳi ght male cancers and support those a ff fected by these devastating diseases.

Data released in January 2025 showed that early cancer diagnosis relating to 13 of the most common cancers in England had reached the highest ever level. This re fl ects the ongoing e ff forts by healthcare professionals, and the targeted campaigns delivered by charities including Orchid, which have helped achieve this positive outcome.

To help men avoid late diagnoses with poorer outcomes, one major priority last year was to educate people about male cancers, helping them understand who is at risk and to recognise potential signs and symptoms. In response to rising male cancer cases in the UK, Orchid’s Nurse led services were promoted widely. For the fĳi rst time, our Freephone Male Cancer Helpline was available 5 days a week, o ff fering con fĳi dential support and information to callers, as well as signposting to other Orchid services.

The composition of the Board was discussed throughout the year. This led to a governance audit in Spring 2025 using the template of the Charity Governance Code and the Charity Commission's governance recommendations. As a result of this exercise, a decision was made to reduce the size of the Board. From April 2025 a consolidated and focussed group of Trustees became responsible for the good governance of our charity.

Orchid’s roots are in research and last year we were delighted to support two di ff ferent research areas. One was the Robert Lane Tissue Bank, and the other work explored whether bacteria could be used to predict who will develop aggressive or recurring prostate cancer.

Having stepped down as a Trustee and Chair of the Board of Trustees, I was delighted to accept the invitation to continue to play a role in Orchid as an Honorary President. Professor Tim Oliver also became an Honorary President in recognition of his signi fĳi cant contribution to the charity.

Orchid was so proud when, out of over 500 applications, our charity was announced as one of ten winners of a 2024 GSK Impact Award in March. The awards are run in partnership with The King’s Fund and recognise and reward charities doing outstanding work to improve people's health and wellbeing. This award provides Orchid with an important quality mark.

I would like to thank all the Trustees who served from the beginning of the reporting year onwards and who participated in the governance review and then stepped down in April. We remain very grateful for their o ff fers of support and best wishes for the future.

Ali Orhan continued to lead the charity throughout the year. His was a dual role of CEO and Director of the Overcoming the Barriers to Engaging with Prostate Cancer programme for the fĳi rst part of the year, and then from August, Director of the Active Participation in Male Cancer Awareness in Prisons programme. We are grateful to the National Lottery Community Fund for their support for these two innovative pieces of work.

As we move forward, we remain committed to saving men’s lives from prostate, testicular and penile cancer. This will only be possible with the help of our many supporters and volunteers who champion our work. Thank you to you all.

Colin Osborne MBE

Orch i d – here today, g i v i ng hope for the future

s CEO of the Orchid Cancer Appeal, it is my honour to re fl ect on the remarkable progress we have achieved together over the past year, from October 2023 to

The year’s accomplishments are a testament to the unwavering dedication of our donors, fundraisers, volunteers, sta ff f, and trustees. In a challenging year for our fundraising, your support has been the cornerstone of our success, and we are deeply grateful for your commitment to this critical cause.

A

September 2024. This period has been one of growth, innovation, and dedication as we continued our mission to combat male-speci fĳi c cancers.

We were privileged to have one of our Trustees join the sta ff f team to lead a strategic planning day, a pivotal step in shaping our future direction and developing operational plans. This collaborative e ff fort re fl ects our shared commitment to tackling male-speci fĳi c cancers with renewed focus and purpose.

We have made signi fĳi cant strides in raising awareness, expanding support services, and advancing research. Key achievements during this time include:

Community outreach: 2024 saw the completion of the Overcoming the Barriers to Engaging with Prostate Cancer programme. Through this a dedicated team of Volunteer Community Champions worked tirelessly for 3 years across ten cities outside London, reaching an incredible 33,977 individuals with vital information about prostate cancer.

With your support, Orchid remains strong, committed, and ready to face the future. As we look ahead, we do so with optimism, determination, and an unyielding dedication to our mission. Together, we will continue to save lives, support families, and drive forward in the fĳi ght against male cancers. Thank you for standing with us.

Penile Cancer Programme: With the securing of new funding, we initiated the Four Nations Penile Cancer Programme. This e ff fort is aimed at raising awareness and enhancing support for those a ff fected by this rare but impactful condition.

With gratitude Ali Orhan CEO, Orchid Cancer Appeal

Support services : Our Freephone Con fĳi dential Helpline has remained a lifeline for those a ff fected by male-speci fĳi c cancers. Additionally, a specialised telephone counselling service was made available to support those navigating penile and testicular cancer diagnoses.
Male Cancer Awareness Week: September 2024’s digital campaign which reached over 400,000 people had a nostalgic feel with a “Focus on Facts.” The Week saw a series of posts about prostate, testicular and penile cancer, and the support Orchid can o ff fer.
Research advancements: In our commitment to advancing scienti fĳi c understanding, we increased our investment in research, awarding grants for innovative prostate cancer studies. The Robert Lane Tissue Bank, a vital international resource for research into male-speci fĳi c cancers, continues to be at the forefront of our e ff forts.

We have made s i gn ifĳ icant str i des i n ra i s i ng awareness, expand i ng support serv i ces, and advanc i ng research

Annual report and fĳ inanc i al statements 2023–2024 | ORCHID CANCER APPEAL

ORCHID CANCER APPEAL | Annual report and fĳ inanc i al statements 2023–2024

The year in review

1 October 2023 – 30 September 2024

LEFT: The Orch i d team accept i ng the award at the 2024 GSK IMPACT Awards

he incidence of prostate, testicular and years ago, our two part-time Male Cancer Nurse penile cancer has been increasing, and there Specialists were on hand to support callers from 9am to is currently an annual combined total of over 5.30pm Monday to Friday. Accurate information about T 58,000 new cases each year in the UK. penile cancer is hard to fĳi nd, and during the year, These cancers can be aggressive, life-changing, and around 50% of calls related to this rare cancer. devastating to families. Furthermore, they can strike at Calling the Helpline makes a di ff ference and in 2023any age and in any walk of life. While medical 2024, 80% of people said calling the Helpline and advancements have improved outcomes, many men are speaking to an Orchid Male Cancer Nurse Specialist still diagnosed too late and over 12,000 lives are lost to helped them with their query, and 90% of healthcare these cancers each year in the UK. professionals felt it helped them with a patient.

T

In response to the rising numbers of people diagnosed, and the impact of a diagnosis, Orchid worked throughout the year to support anyone a ff fected through our Nurse-led services. We also worked across the four nations to help people learn about risk factors, potential signs and symptoms, and the bene fĳi ts of an early diagnosis. Additionally, the charity invested in research to bene fĳi t both current and future generations of men, supporting two areas of work in the year.

Positive feedback, unique service

Orchid continued to o ff fer our telephone counselling service for those diagnosed with the rare testicular or penile cancer. Nurses on the Helpline assessed callers’ needs, and where relevant, men were referred to this unique service.

Evaluation is positive, and in the words of one man who bene fĳi ted during the year: “I was supported, listened to and guided in a way that helped me adjust to the new me, be prepared for the what ifs of surgery and treatment, realise that no matter the outcome, I could still fĳi nd joy in my body.” To complement and supplement existing services, a new o ff fer of mentoring for men who have been diagnosed with testicular cancer was introduced.

Mark of Excellence

It was a huge honour that Orchid’s work was recognised when the charity was announced as one of ten winners of a 2024 GSK IMPACT Award (run in partnership with The King’s Fund). These awards recognise charities doing outstanding work to improve people's health and wellbeing. The award name ‘IMPACT’ comes from: Innovation, Management, Partnership, Achievement, Community focus and Targeting need, and we were proud that assessment showed our work and charity to meet those demanding criteria.

On the road again

Cancers found early are often the easiest to treat with the best prognosis, and therefore male cancer education remained a priority. Day long Male Cancer Information Roadshows were delivered in the heart of targeted communities and provided 7,703 people with the opportunity to learn about male cancers and talk about any concerns. Our reach through our Health at Work talks increased, as our Male Cancer Nurse Specialists delivered informative talks both in person and virtually with the latter bringing a wider geographical reach.

Double the reach

Orchid increased our reach during the year. For example, the number of male cancer lea fl ets, booklets and posters distributed through awareness activities such as Roadshows, our Volunteer Community Champions, talk and presentations was more than double that of the year before.

Focusing on facts

Helpline increase

Social media and digital activity continued to play a huge role in educating people about male cancers and the bespoke support services Orchid can o ff fer. One

The hours of the Orchid Male Cancer Helpline increased, and for the fĳi rst time since it was set up ten

Annual report and fĳ inanc i al statements 2023–2024 | ORCHID CANCER APPEAL

ORCHID CANCER APPEAL | Annual report and fĳ inanc i al statements 2023–2024

‘Focus on Facts’ dur i ng Male Cancer Awareness Week took i nsp i rat i on from mechan i cs’ manual to set out the facts and fĳ igures assoc i ated w i th each of the male cancers.

example was Orchid’s Male Cancer Awareness Week in 2024 ‘A Focus on Facts’ which highlighted information about each of the male cancers and how Orchid can help, and we are grateful to our partners for sharing these important messages. Another successful social media campaign was ‘Warn a Brother’ which highlighted the increased incidence of prostate cancer in Black African and Black Caribbean men.

Barriers overcome

Alongside our core activities, Orchid delivered targeted projects and activities throughout the year. Overcoming the barriers to engaging with prostate cancer, our three-year project funded by the National Lottery Community Fund ended in the Spring. Through this we trained Volunteer Community Champions to cascade prostate cancer messaging in ten locations in England.

HMP Orchid

We were delighted when further three-year funding was granted by the National Lottery Community Fund to deliver Active participation in male cancer awareness in prisons, which incorporates some learnings from the previous Lottery funded work. This new programme began in August.

Four nations, one programme

Despite being the rarest of the three male-speci fĳi c cancers, penile cancer will often cause the most severe physical and psychological side e ff fects, yet awareness of penile cancer is low even amongst healthcare professionals. Orchid’s Four Nations Penile Cancer Programme was launched at the beginning of the year to address these issues and to help men cope with the isolation of a diagnosis and the di f i culties they face in managing the physical and psychological impact of the disease.

National conference

At the heart of our charity is diversity and inclusion. Orchid was proud to work with Cancer Equality to deliver a National Prostate Cancer Awareness Conference to launch Ethnic Minority Cancer Awareness Month in July. This was attended by

patients, healthcare professionals and service providers and explored the experience of Black African and Black Caribbean men diagnosed with prostate cancer.

Diverse communities

In response to the increased incidence within this community Orchid delivered a Prostate Cancer and Faith project in Birmingham and London through which we delivered talks in faith settings with a predominantly Black African and Black Caribbean congregation. Our work to reach trans women at risk of prostate cancer continued including via a social media campaign, and a new project began to raise awareness of male cancers within the Deaf community with Orchid speakers supported by a British Sign Language interpreter.

Download here

Orchid information in the form of lea fl ets, booklets, and short fĳi lms/videos and the charity’s website (where resources can be downloaded) is subject to regular reviews to ensure it contains the most up-to-date, accurate and accessible information to meet the needs of men. Some was updated during the year and a new short fĳi lm Living with Advance Prostate Cancer was added to the portfolio.

On the European stage

Orchid’s position as a key patient advocacy organisation within the European urological landscape was further strengthened during the year through its continued role in collaboration with the European Association of Urology (EAU) and the European Reference Network for Rare Urogenital Diseases (eUROGEN). As the only male cancer charity in Europe with membership of these in fl uential networks, we are proud that Orchid continued to help shape the future of care for the rare penile and testicular cancers.

Forecourt and foyer

At the year-end funding was received to deliver a prostate cancer awareness campaign in petrol stations entitled Every last Drop, and a community play in Nottingham called Prostate not Prostate working with a local partner.

Thank you

Orchid’s work can only happen thanks to the generosity of our supporters. We could not deliver our Nurse-led services, targeted programmes or fund research without donations and grants from individuals, community and faith groups, the National Lottery Community Fund, Trusts and Foundations and our corporate supporters. We o ff fer our heartfelt thanks to you all.

Annual report and fĳ inanc i al statements 2023–2024 | ORCHID CANCER APPEAL

ORCHID CANCER APPEAL | Annual report and fĳ inanc i al statements 2023–2024

Fundraising

rchid is committed to generating funds from diverse income streams to balance risk and to provide sustainable income to ensure we can continue to deliver our education and

O

awareness programme and Nurse-led services, as well as to fund innovative male cancer research. We thank each and every one of our most wonderful supporters who raised funds or gave us donations in the year, be they individuals, community groups, sports clubs, schools, Companies, Charitable Trusts or Foundations, or The National Lottery Community Fund.

Many Orchid supporters have a connection to our cause, perhaps because they, or someone they know, have been touched by male cancer. People also pay tribute to loved ones by giving in their memory. Individuals contributing through Payroll giving schemes continued to provide a valuable source of unrestricted income.

We are truly humbled by the dedication of our fundraisers and supporters, which is why our small team were there to cheer on runners at events such as the London Marathon and the London Landmarks Half Marathon. Where we could not be there in person, we helped and encouraged individuals and groups across the UK. Examples of some of the wonderful fundraising events in the last year include cake sales and tea parties; fundraising events in schools; challenge and sporting events from walks, a cricket match and bike rides, to mountain climbs, tough mudders, a 24 Charity Race and the Southern Scale Trail; and the annual Twyford Beer Festival.

Grants from Charitable Trusts and Companies enabled Orchid to provide male cancer information in di ff ferent formats and settings, support those a ff fected via nurse-led services, and to deliver innovative awareness activities. We were delighted to receive news of new three-year funding from The National Lottery Community Fund to deliver a new programme entitled “Active Male Cancer Awareness in Prisons” which started in August and will roll out to all prisons in England. We enjoy reporting back to funders to show the impact of their funding.

A total of £767,210 was raised during the year which was a slight increase on the previous year’s income.

Under the leadership of a part time Head of Fundraising, the small fundraising team continued to review our activities using both our own learnings and that of the wider fundraising sector, and sought to identify new opportunities to ensure we retain a diverse and cost-e ff fective fundraising base to balance risk in the years ahead.

Orchid continually strives to meet and maintain high standards in all areas of fundraising and recognises the importance of listening to and putting supporters at the centre of everything that we do. We are registered with the Fundraising Regulator and adhere to the Code of Fundraising Practice when carrying out our activities. Our sta ff f are committed to following codes of good practice and standards developed by the fundraising community through the work of the Chartered Institute of Fundraising and other professional bodies. Orchid operates a clear and stringent complaints handling procedure that is reported to senior management and the Board of Trustees.

As part of our supporter care programme, we have agreed policies and procedures in place and written agreements with any external agencies we engage to help us or who raise funds for the Charity. We ensure that anyone engaged to work for us is trained in and respects our aims and objectives and carries out their activities with the same high standards and care we would ourselves.

During the year we received three complaints in relation to our fundraising activities which were resolved swiftly in line with our procedures. We remain committed to improving our practice, learning from supporter feedback.

Pedal for Pride, Fight for Life!

fter a routine bike ride that turned serious when he discovered a worrying symptom, Jadem knows the importance of early A diagnosis, and wanted to use his experience as a powerful reminder to listen to your body and seek help and support at the earliest possible stage. LDN RIDERS knew they wanted to celebrate Jadem’s triumph over testicular cancer and empower others facing cancer with con fĳi dence. Forty LDN RIDERS came together to take on a London to Manchester cycle – a gruelling 360 kilometres with over 3,600 meters of elevation – that's more than three times the height of Mount Snowdon! They chose Orchid as we provide invaluable support to those facing male cancers, just like Jadem – the LDN Riders are passionately supporting our life-saving research, support services, and public awareness initiatives.

Their dedication shone through, not only in completing the physical challenge, but in their tireless fundraising: they fĳi nished with a fantastic total of £5,318.

Forty LDN RIDERS rode a gruell i ng 360 k i lometres and ra i sed a total of £5,318 to support Orch i d’s l i fe-sav i ng work.

“A huge shoutout to our amaz i ng r i ders who cycled 360km from London to Manchester, and to everyone who donated. Your support means the world to us and w i ll make a real d iff ference i n the l i ves of those a ff fected by cancer”

Annual report and fĳ inanc i al statements 2023–2024 | ORCHID CANCER APPEAL

ORCHID CANCER APPEAL | Annual report and fĳ inanc i al statements 2023–2024

Orchid’s collaborative role in European urological initiatives

A

s the only male cancer charity in Europe with membership of these in fl uential networks, Orchid continued to help shape A the future of care for the rare penile and testicular cancers during the reporting year. This work was driven by Orchid’s Male Cancer Information Nurse Specialist, Rob Cornes.

European Association of Urology EAU Testicular Cancer Guidelines panel

As an active patient advocate member of the European Association of Urology (see box, right) Testicular Cancer Guidelines panel, Rob’s involvement has ensured that patient quality of life and unmet needs are considered at the forefront of new treatment guidelines. Future initiatives may involve the creation of patient-friendly resources revolving around shared decision-making to improve communication between clinicians and patients.

EAU Patient Advocacy Group

Orchid is currently also a member of the EAU Patient Advocacy Group (EPAG), an initiative created by the EAU Patient O f i ce. Rob is a patient advocate for both penile and testicular cancer within this group. The EPAG consists of organisations, charities and disease coalitions from all over Europe who work with the Patient O f i ce to ensure that patient advocacy is promoted wherever possible. This involves the creation of information and resources designed to help patients understand and manage conditions which are used throughout Europe.

Orchid’s involvement has helped to create vital resources and deliver patient-centric talks across Europe. This collaboration has led to initiatives such as a Penile Cancer Roundtable at the EAU Congress 2024, which Rob facilitated, involving patients and clinicians. It also led to the creation of the EAU penile cancer animation which Rob helped script in 2023 which includes an overview of treatment and importance of

European Assoc i at i on of Urology

The European Association of Urology (EAU) is the biggest urological association in the world with a network of 19,000 urologists throughout Europe. It undertakes the teaching and education of urologists, research projects and initiatives to treat urological disease. These projects and information are disseminated via an annual European Congress.

In addition, the EAU creates guidelines for the treatment of every urological condition. Although the UK has NICE Guidelines for prostate cancer, there are none for penile or testicular cancer. Recommendations for treatment of these diseases is currently derived from the European Association of Urology (EAU) Guidelines. These guidelines are compiled by individual expert panels, made up of urologists, oncologists, histopathologists and radiologists as well as patient advocates.

psychological support for patients which was instigated by Rob. Two versions of this video were created (English and Spanish) with a combined total of 78,000 worldwide views so far.

As a member of the EPAG Rob will be involved in future initiatives to improve patient outcomes and experience for prostate, testicular and penile cancer.

Annual report and fĳ inanc i al statements 2023–2024 | ORCHID CANCER APPEAL

Thank you to our incredible Orchid volunteers!

European Reference Network for Rare Urogenital Diseases ERN (eUROGEN)

Orchid’s collaboration with eUROGEN (see box, right) further solidi fĳi es its role in advocating for the rare urological diseases, and Orchid is a member of Workstream 3. Rob is the o f i cial patient advocate for both penile and testicular cancer within this group, along with two penile cancer advocates who were introduced through Orchid’s support.

Rob has given several talks at the EAU Congress discussing the unmet needs of testicular and penile cancer patients and working with the other advocates has helped create a Patient Pathway for penile cancer. He has also taken part in three international webinars discussing the needs of testicular and penile cancer patients and has contributed to the recent eUROGEN publication Rare and Complex Urology. eUROGEN also provided the funding for the EAU penile cancer animation mentioned above, as well as advocate Richard Stamp’s video Ignore It, dedicated to raising awareness of penile cancer.

Future initiatives will involve the creation of more in-depth documentation of patient journeys for clinical reference.

What this collaboration means for patients

Orchid has been particularly impactful through Rob’s advocacy. Rob and the advocates introduced by Orchid are playing a pivotal role in shaping clinical pathways and patient journeys.

Orchid is set to continue leading patient advocacy initiatives by bringing our insight and experience to initiatives and projects created by clinicians who will ultimately be responsible for shaping future care and patient outcomes throughout Europe and the UK. These collaborations will ensure that the needs of penile and testicular cancer patients are recognised, and outcomes improved.

European Reference Network for Rare Urogen i tal D i seases ERN (eUROGEN)

This is a European organisation which works alongside the European Commission to provide equitable care throughout Europe to patients with rare urological disease including penile and testicular cancer. It is split into various workstreams which are made up of urologists. oncologists and patient advocates.

BELOW: At h i s EAU24 presentat i on, Orch i d Nurse Rob Cornes descr i bed how v i rtual support groups can help problems assoc i ated w i th test i cular cancer treatment and recovery, by transcend i ng phys i cal barr i ers and br i ng i ng those a ff fected together w i th healthcare profess i onals.

olunteers are the heart and soul of

V

Orchid. As a small charity, we rely on the dedication and generosity of those who give their time to support our mission. Whether it’s raising awareness, cheering on our runners at events, or helping to raise much-needed funds, every volunteer plays a vital role in the fĳi ght against male cancers.

Trevor’s impact is remarkable: in just twelve months, he has distributed over 18,332 male cancer resources, empowering individuals with knowledge about their health and when to seek medical advice if concerned. His dedication has not only raised awareness but has undoubtedly saved lives.

O ne of our most passionate and dedicated volunteers, Trevor, has been an extraordinary force in educating thousands about prostate, testicular, and penile cancer. His commitment to spreading awareness has made a tangible di ff ference in communities across Hillingdon, Harrow, Ruislip, and Ealing.

O

Trevor, your passion, hard work, and unwavering enthusiasm have made a real

Over the past year alone, Trevor delivered an astounding 88 awareness activities, reaching people in gyms, libraries, supermarkets, shopping centres, faith groups, and other community settings. His e ff forts have helped ensure that more men recognise the risks, symptoms, and understand the importance of early detection.

and lasting di ff ference. From all of us at Orchid, thank you for being such an incredible part of our mission. We are truly grateful for everything you do.

To all our volunteers – thank you for standing with us in the fĳi ght against male cancers. We couldn’t do this without you!

----- Start of picture text -----
Volunteer spotlight | TREVOR
----- End of picture text -----

Annual report and fĳ inanc i al statements 2023–2024 | ORCHID CANCER APPEAL

ORCHID CANCER APPEAL | Annual report and fĳ inanc i al statements 2023–2024

Orchid wins top UK health award

research driven focus, they have a substantial reach and impact to support the cancer community.”

ollowing a rigorous selection and assessment process, Orchid was proud to be chosen from more than 500 charities across the UK F as one of the 10 winners of the 2024 GSK IMPACT Awards which are delivered in partnership with The King’s Fund.

As an award winner, Orchid received £40,000 in unrestricted funding as well as both an ‘explainer’ fĳi lm about our work and social media assets which have been helping us showcase our work to supporters and potential partners.

Now in its 27th year, the awards are a mark of excellence in the charity sector, designed to recognise the outstanding work of small and medium-sized charities working to improve people’s health and wellbeing in the UK.

Another element of the award Orchid bene fĳi ted from is expert support and leadership development provided by leading health and care charity, The King’s Fund. Orchid attended the three-day GSK IMPACT Awards Development Programme which is tailored to the needs of each year’s award winners.

The award judges commented positively about the wide-ranging work Orchid does to raise awareness amongst members of the public as well as healthcare professionals; our determination to target communities most in need; our services; and our ability to build strong partnerships across the health and charity sectors to amplify our reach.

Orchid is now a member of the GSK IMPACT Awards Network, which connects past award winners, both online and at meetings. The aim of the Network is to develop charity leaders on an ongoing basis, providing them with the skills to respond to the challenges of their environment and to share experiences and expertise. It also provides an opportunity to build the recognition of their signi fĳi cant and vital contribution to the health and social care system.

The award judges also praised the charity’s work to improve understanding of male-speci fĳi c cancers including possible causes, potential new treatments and ways of enhancing care, mentioning the research carried out in the Robert Lane Tissue Bank.

Orchid is particularly grateful to Patrick Meehan who shared his penile cancer journey and the support he received via our Helpline and penile cancer counselling service as part of our fĳi lm. We were absolutely delighted that he joined Orchid CEO Ali Orhan on stage at the awards ceremony to collect our award.

Lisa Weaks, Senior Associate at The King’s Fund, said: “Through its creative and inclusive approach, Orchid Cancer Appeal has developed a unique way of reaching those who are more likely to be diagnosed with male speci fĳi c cancers and is working hard to reduce the gap in poor health outcomes across di ff ferent communities. It spreads awareness of signs and symptoms, supports those who are diagnosed with these often-devastating diseases, and funds research into the causes and treatment of cancer. For a small charity with very few sta ff f, through their tireless campaigning and

Orchid would like to thank GSK and The King’s Fund for recognising our contribution to improving the health of people across the Four Nations. This award will help take the charity forward with the ultimate goal of reaching more people at risk of prostate, testicular or penile cancer and better supporting those living with a diagnosis.

‘Through its creative and inclusive approach, Orchid has developed a unique way of reaching those who are more likely to be diagnosed with male speci fi c cancers’

L i sa Weaks, Sen i or Assoc i ate, The K i ng’s Fund

Annual report and fĳ inanc i al statements 2023–2024 | ORCHID CANCER APPEAL

ORCHID CANCER APPEAL | Annual report and fĳ inanc i al statements 2023–2024

69,528 male cancer lea fl ets, booklets and posters were d i str i buted through awareness act i v i t i es such as Roadshows, our Volunteer Commun i ty Champ i ons, talks and presentat i ons. Th i s was more than double the amount i n the prev i ous year.

Through the awareness i ntervent i ons of Orch i d Commun i ty Champ i ons and exper i enced volunteers, 21,744 people were able to learn about prostate cancer.

Annual report and fĳ inanc i al statements 2023–2024 | ORCHID CANCER APPEAL

ORCHID CANCER APPEAL | Annual report and fĳ inanc i al statements 2023–2024

On the road with Orchid’s Male Cancer Roadshows

rchid’s Male Cancer Information Roadshows are informative and engaging. They are delivered in busy locations in the heart of O local communities by our experienced Community Engagement Team.

“It’s so i mportant to know these th i ngs and I agree that men are awful at th i s health th i ng. I’ve moved and st i ll haven’t even reg i stered w i th my new GP... couldn’t even tell you where i t was! I’ll go and get s i gned up now and be wary of these th i ngs i n the future.”

Roadshows provide an opportunity for local people to fĳi nd out about male cancers in a familiar environment and can act as a sounding board for people to discuss male cancer concerns.

“I d i dn't even know you could be more at r i sk for be i ng Black! I'll de fĳ in i tely have a read of th i s booklet now. Thanks mate.”

We particularly target locations in areas of deprivation to reach people who may miss mainstream health education and who might not be able to prioritise their health.

“I'm usually embarrassed about i t but you're so helpful.”

In the year, our team delivered 21 Roadshows giving 7,703 people the opportunity to learn about prostate, testicular and penile cancers.

“To be honest w i th you, I d i dn’t even know what a prostate i s and I’m scared to google i t to see what comes up!”

“Oh we d i dn’t know all of those symptoms, we just thought those were parts of gett i ng older!”

“Yeah, i t’s about t i me I started look i ng i nto my health, I’ve used and abused my body so far w i thout so much as a check-up, so i t’s well overdue!”

Annual report and fĳ inanc i al statements 2023–2024 | ORCHID CANCER APPEAL

ORCHID CANCER APPEAL | Annual report and fĳ inanc i al statements 2023–2024

Social media: a vital tool for changing lives

Warn-a-Brother

“Over the past year, we've

seen strong engagement w i th educat i onal

posts, personal stor i es, and

awareness

i campa gns,

h i ghl i ght i ng the

need for

cont i nued d i g i tal

outreach.”

ocial media has been a vital tool for Orchid throughout the last reporting year, allowing us to raise awareness, share lifesaving S information, and engage directly with those a ff fected by male cancers.

From 1 October 2023 to 30 September 2024, Orchid reached a total of 235,446 accounts through our Facebook, X, Instagram, TikTok and LinkedIn platforms. Our social media channels have helped us reach wider audiences, break down stigmas, and drive people to essential resources.

Over the past year, we've seen strong engagement with educational posts, personal stories, and awareness campaigns, highlighting the need for continued digital outreach.

Moving forward, expanding our reach through targeted content, collaborations, and interactive campaigns will be key to strengthening our impact and ensuring more men have access to the information they need.

iversity and inclusion run throughout Orchid, and we strive to sustainably D and consistently reach people who do not have equal access to awareness and support in their cancer journeys. This is why that as well as using our own platforms, we also use paid advertising on social media to increase our reach and target our campaigns.

One example is our successful and impactful Warn-a-Brother campaign which was delivered in March 2024 using striking images and words. The campaign was delivered in response to the fact that Black African and Black Caribbean men are at increased risk of prostate cancer. Data shows they are more likely to be diagnosed younger and at a later stage than other men, and with a more aggressive type of disease.

The term 'brother' is commonly used in the Black community, and so the campaign was based on this play on words. Alongside that. the images used in the campaign focused on mouths to symbolise speaking up – speaking to your brother, father, friend, and telling them about prostate cancer.

The Warn-a-Brother campaign intervention. It complemented used social media to target Black other Orchid awareness initiatives. communities in London and We were delighted to achieve a Birmingham to raise awareness reach of over 100,000 Black men around their risk of prostate cancer. with total clicks of over 2,000 Its aim was to change the way in through Facebook and Instagram. which Black African and Black As one user posted: “This Caribbean men understand, campaign has made me stop and respond, and promote information think about what I should be doing about what is now the most to help raise prostate cancer common cancer in the UK, and to awareness amongst my encourage them to seek early community.”

Annual report and fĳ inanc i al statements 2023–2024 | ORCHID CANCER APPEAL

ORCHID CANCER APPEAL | Annual report and fĳ inanc i al statements 2023–2024

n March 2021, Orchid was awarded funding from the National Lottery Community Fund to deliver a three-year programme in ten identi fĳi ed areas of I England, aimed at overcoming the barriers to engaging with prostate cancer.

Overcoming I the Barriers to Engaging with Prostate Cancer

The programme was developed in response to the rising number of cases of prostate cancer; low awareness of risk factors, signs and symptoms even amongst those at increased risk; the high number of late diagnoses; and the negative impact this has on treatment options and outcomes.

The aim of the programme was to develop a regional network of Volunteer Community Champions who would deliver awareness raising and information sharing, especially among high-risk groups (for example marginalised communities) for whom barriers to engaging with the issue are greatest.

Overcoming the Barriers to Engaging with Prostate Cancer launched on 4 May 2021 and ran until 3 May 2024. It was delivered in the following ten locations: Birmingham, Bradford, Bristol, Dudley, Leeds, Liverpool, Manchester, Newcastle, Nottingham, and Wolverhampton. Orchid is proud of what the programme achieved, and independent evaluation of the programme can be found on the Orchid website.

“That knowledge i s there, i n the back of your m i nd. It doesn’t leave you and i s there to feed i nto your work and l i fe. Even i f formally you are not work i ng as a champ i on, you st i ll are i n pr i nc i ple and pract i ce. I w i ll not forget what I’ve learnt and w i ll look for opportun i t i es to share i t w i th those around me.”

Over the three years a total of 168 Volunteer Community Champions were recruited, trained and supported by the Orchid team. Champions brought a wide range of skills and experience, and our team of Champions was made up of community members including people with lived experience, members of partner organisations, healthcare professionals, and prison residents. What they all had in common however, is that they were passionate about getting people in their communities talking about prostate cancer.

Champions were empowered to use their own networks and ideas to book activities and to reach members of their local communities. For example, some Champions ran information stalls in markets, libraries and at festivals, and others attended men’s groups, gave talks, or disseminated information at food banks. 37 men in prisons cascaded information to other prison residents.

Whilst Champions may have delivered di ff ferent activities, they all only did so after structured training by the Orchid team. Each Champion was issued with an Orchid prostate cancer tool kit full of easy-to-follow information and pictures to help them convey information in an accurate manner, and to ensure they had the answers to commonly asked questions. Refresher training was also available to Champions, as well as opportunities to meet others for ongoing learning and peer support.

Volunteer Community Champion

Through their chosen activities, Champions disseminated prostate cancer fact sheets which were accessible and engaging for the programme’s target audience. This lea fl et, which some Champions had helped develop, included details of Orchid’s website and Freephone Male Cancer Helpline for more information. It was complemented by regionalised signposting lea fl ets which were distributed by the Community Champions as part of their engagement activity.

Through the e ff forts of our Community Champions over the 36 months, 34,577 people engaged with the programme to learn about prostate cancer. Furthermore, Champions disseminated 22,000 prostate cancer factsheets and over 8,000 signposting lea fl ets.

Measuring impact was an important part of the programme both in relation to the Champions themselves as well as the bene fĳi ciaries. Being a Community Champion provided meaningful opportunities for people with lived experience to pursue a subject of importance to them and develop their own awareness, knowledge and skills, as well as improving Champions’ self-esteem and con fĳi dence.

People who engaged with the programme identi fĳi ed positive impacts of their engagement, including increased awareness and knowledge relating to prostate cancer and increased con fĳi dence to access healthcare services.

One example that a Community Champion from a partner healthcare organisation fed back to Orchid is: “One woman came to us and was worried about her husband who she noticed was going to the toilet more during the night. She spoke with us and we gave her a lea fl et. This gave her the tools to speak with her

ABOVE: Attendees husband and I know that she encouraged him to go to at the conference the doctors. She got back in touch to say that they had held to mark the detected it early and he is OK now.” This example also end of the three shows the important role that women can play in the programme health of men in their lives.

Orchid would like to thank The National Lottery Community Fund for their grant which enabled us to train 168 wonderful Community Champions who reached 34,577 people with prostate cancer information. In turn we would like to thank the Champions who gave their time and passion freely and helped Orchid deliver such a successful programme. We would also like to thank the ten members of a Task Force recruited at the beginning of the programme, and which included senior and strategic level representation from organisations across England. Members helped shape the programme, provided access to networks and groups to support volunteer recruitment and to cascade information, and gave invaluable input into the design of resources.

The programme left a lasting legacy of a pool of knowledge, training and resources with which Community Champions can continue promoting awareness of prostate cancer, whether that be formally or informally in their everyday lives.

webs | i te and 11,386 v i ews on Orch i d’s test i i cular Je cancer m i cros i te Your Pr i vates. “a ‘ 7 : : *- Bat | a. We reached a total of 235,446 accounts through Orch i d’s ive soc i al med i 2 ais fĳ a platforms. - “ee Set

Annual report and fĳ inanc i al statements 2023–2024 | ORCHID CANCER APPEAL

ORCHID CANCER APPEAL | Annual report and fĳ inanc i al statements 2023–2024

‘Orchid was proud to work with Cancer Equality to deliver a conference dedicated to exploring the experience of Black African and Black Caribbean men diagnosed with prostate cancer.’

Prostate cancer

Prostate cancer i s the most common cancer i n men i n the UK w i th an annual i nc i dence of over 55,000. Sadly around 12,000 men w i ll d i e from the d i sease each year, a level wh i ch has rema i ned stable over the last fĳ ive years suggest i ng an i mprovement i n overall mortal i ty. However, up to 25% of men are d i agnosed w i th i sease. late-stage d

he incidence for men of Black African and Black Caribbean descent T remains twice that of Caucasian men along with family history in a fĳi rst degree relative and a family history of the BRCA gene responsible for genetic breast cancer. Orchid continues to engage with men from these high-risk communities. Debate around UK screening programmes continues, and various trials/research initiatives have been launched to identify the most relevant way forward although it is still likely to be a few years before agreement is reached.

Active surveillance continues to be the preferred option for men with low grade prostate cancer while di ff ferent approaches to more advanced but curable disease are being evaluated for less invasive (focal) treatments.

With over 110 prostate cancer support groups now existing in the UK, face to face and virtual peer support for those diagnosed continues to grow, while many celebrities who have been a ff fected by the disease, talk freely about their experience which serves to promote awareness of the disease.

National Prostate Cancer Awareness Conference

July is Ethnic Minority Cancer Awareness Month which is driven by the charity Cancer Equality to shine a light on the issues a ff fecting Minority Ethnic Communities and cancer.

This year Orchid was proud to work with Cancer Equality to

Annual report and fĳ inanc i al statements 2023–2024 | ORCHID CANCER APPEAL

ORCHID CANCER APPEAL | Annual report and fĳ inanc i al statements 2023–2024

Sally’s story

deliver a National Prostate Cancer Awareness Conference at the Royal College of Nursing in London to celebrate the beginning of the Month. It was attended by patients, healthcare professionals and service providers.

The conference was dedicated to exploring the experience of Black African and Black Caribbean men diagnosed with prostate cancer. It was an excellent chance for those in attendance to learn fĳi rst-hand from healthcare professionals and patients the problems and inequalities associated with raising awareness of prostate cancer and supporting men within this community.

Speakers included Klark Mullen, Government A ff fairs Lead at Astellas Pharma, who discussed inequalities, Dr Eva McGrowder (Institute of Cancer Research) who gave an overview of the PROFILE study and Rebecca Todd (UCH) who presented information on the TRANSFORM study. Personal experience was provided by Sally Green (see case study on following page) and Maurice Blake while Marcella Turner, CEO of Manchester based charity CanSurvive UK, discussed the need for the development of culturally appropriate information.

Feedback was extremely positive, and it provided opportunities for improved partnership working. From 2025 Orchid will now be the lead charity on Ethnic Minority Cancer Awareness Month.

RIGHT: The Nat i onal Prostate Cancer Awareness Conference at the Royal College of Nurs i ng i n London was attended by pat i ents, healthcare profess i onals and serv i ce prov i ders.

“We have lost ally’s unwavering passion talks in churches across London for raising awareness about and Birmingham, engaging prostate cancer, especially predominantly Black congregations. S among Black African and These e ff forts aimed to dismantle so many of us Black Caribbean men, stems from a stigmas and create safe spaces to worsh i ppers to deeply personal loss. In 2021, her discuss prostate cancer openly. husband, John, succumbed to this Through Sally’s dedication, over prostate cancer. disease, leaving behind not just a grieving family but also a powerful 2,750 individuals gained crucial knowledge about prostate cancer legacy of education and support. risk factors and early warning signs. Th i s knowledge John found solace and In these familiar and supportive camaraderie as a regular member of environments, attendees were w i ll help us to be an Orchid support group, where he equipped to share this vital shared stories, found strength, and information with others. As one aware of the s i gns even laughter with other men a ff fected by cancer. For Sally and her congregation member put it: “We have lost so many of us worshippers family, these support networks to prostate cancer. This knowledge and symptoms became a beacon of hope during will help us to be aware of the signs di f i cult times. They expressed and symptoms and, most and, most heartfelt gratitude for the importantly, seek medical help soon.” invaluable assistance Orchid Sally’s tireless commitment i mportantly, provided during their journey. continues to transform lives, Inspired by John’s experiences, spreading awareness, fostering seek med i cal Sally collaborated with Orchid to community engagement, and share his story in one of three honouring John’s memory in the impactful fĳi lms aimed at raising most impactful way possible. Her help soon.” awareness of male cancers. These story is a testament to the power of fĳi lms have since reached and love, faith, and resilience in the touched countless lives. face of loss. Orchid recognises Sally’s incredible contributions, particularly her moving speech at the National Prostate Cancer Awareness Conference, which stood out as a highlight of the event. Her words resonated deeply, inspiring action, and fostering understanding about the importance of early detection and support. At the core of Sally’s advocacy is her faith, which became the driving force behind Orchid’s groundbreaking Prostate Cancer and Faith Project. With Sally’s encouragement, Orchid delivered

----- Start of picture text -----
ORCHID CANCER APPEAL | Annual report and fĳ inanc i al statements 2023–2024
----- End of picture text -----

“> a i onals 5,245 men, women and healthcare profess

33 Se = Sey SSCS Sat Si

Annual report and fĳ inanc i al statements 2023–2024 | ORCHID CANCER APPEAL

ORCHID CANCER APPEAL | Annual report and fĳ inanc i al statements 2023–2024

‘Orchid is currently supporting one of the few testicular cancer support groups in the UK. It has an online Facebook group with around 350 members’

Testicular cancer

Test i cular cancer i n the UK a ff fects around 2,400 men a year. Approx i mately 70% of these men w i ll be between the ages of 15-45, although i t can occur at any age. The i nc i dence and mortal i ty (around 65 men d i e each year), have rema i ned stable and constant over the last i n the UK. fĳ ive years

esticular cancer also

T

remains the most treatable and potentially curable cancer with 95% of men, including those with metastatic disease, surviving for 10 years. However, it is important to recognise that to achieve cure men may need to undergo gruelling chemotherapy treatment which will have long term survival implications. Chemotherapy increases the risk of physical illness such as cardiovascular disease, can reduce testosterone levels which may contribute to metabolic syndrome, and can cause temporary, but sometimes permanent side e ff fects, such as poor cognitive function, peripheral neuropathy, and reduced lung function. In addition, the psychological impact of the disease on a predominantly young, less mature age group can often result in severe coping di f i culties. Orchid now provides a unique telephone counselling service which allows men to undergo counselling with a degree of anonymity at a convenient time and at any point in their treatment journey. In addition, Orchid is currently supporting one of the few testicular cancer support groups in the UK. This group meets physically in London and virtually. It has an online closed Facebook group with around 350 members. Orchid Male Cancer Information Nurse Specialist, Rob Cornes, acts as an administrator for the group.

Annual report and fĳ inanc i al statements 2023–2024 | ORCHID CANCER APPEAL

ORCHID CANCER APPEAL | Annual report and fĳ inanc i al statements 2023–2024

Simon’s story: A journey of strength, resilience, and purpose

imon Feldman’s story is one of extraordinary courage, perseverance, S and hope. He has survived testicular cancer not once, not twice, but three times. Now, he shares his experience to inspire conversations, support others, and bring awareness to this journey of resilience.

The battle begins

Simon was fĳi rst diagnosed with testicular cancer at the age of 20 while living as an international student in Australia. In his words, he was “having the time of his life” when his world was suddenly turned upside down. The memory of calling his parents to share the devastating news still stays with him.

Following treatment, a scan revealed that the cancer had spread to his stomach, requiring him to return to London for further treatment. Over the course of several months, he endured three rounds of chemotherapy. It was a gruelling process, but he fought through and slowly began to rebuild his life.

A second battle

Four years later, Simon received another devastating diagnosis – testicular cancer had returned. Facing cancer a second time was incredibly di f i cult, but with surgery and treatment, he once again overcame the disease. Determined not to let cancer de fĳi ne him, Simon set a bold new goal – completing the New York Marathon. Just one year after his

second diagnosis, he crossed the fĳi nish line, proving his resilience and strength.

A third fi ght

Four more years passed. Simon was busy with work, life, and planning his wedding when he was once again blindsided – his third diagnosis of this rare cancer. Another operation followed, but amidst the challenge, Simon and his wife were able to celebrate the wedding of their dreams.

One heartbreaking reality, however, weighed heavily on him: he would not be able to father children naturally. The journey to parenthood was fĳi lled with challenges, but Simon and his wife refused to give up. On their fĳi fth and fĳi nal attempt at IVF, they received the news they had longed for – a positive pregnancy test. Today, they are the proud parents of a beautiful daughter.

Turning pain into purpose: Coaching and giving back

Simon is now a quali fĳi ed coach, dedicating his life to helping others transform their own journeys. Through his generosity and commitment, Orchid was able to o ff fer free coaching to men diagnosed with testicular cancer.

Working alongside these men, Simon helped them rede fĳi ne who they were and supported them in becoming the person they always wanted to be. His experience, empathy, and strength make him

‘Through i t all, an invaluable mentor and source I have learned of inspiration for others facing someth i ng adversity. His passion shines through in i nvaluable: the his words: person who “I know how di f i cult it is to has been there remain strong when you feel weak. for me every To hold on when you want to let go. step of the way But through it all, I have learned i s me.’ something invaluable: the person who has been there for me every step of the way is me.

“I have discovered a strength, determination, and resilience I never gave myself credit for. Now, I am using that strength to change the way I see myself and to help others transform their lives.

“I share my story, so you know this: You are not alone.

“That person staring back at you in the mirror – that’s you. You show up every day, battling through with courage, conviction, and power, even if you don’t see it yet.

“Recognise your strength. Hold on. It will carry you forward through even the hardest days.

“With grit, belief, and the love of those around you, you can keep going. You can keep fĳi ghting. And no matter how dark the storm, it will pass.

“You can. And you will.” Simon’s story is a testament to resilience, the power of the human spirit, and the ability to turn adversity into purpose. Through his journey, he continues to inspire countless others, proving that even in the face of unimaginable challenges, strength, hope, and determination can lead to incredible triumphs.

ORCHID CANCER APPEAL | Annual report and fĳ inanc i al statements 2023–2024 ~~° _ Va.’~~

~~——————~~ Annual report and fĳ inanc i al statements 2023–2024 | ORCHID CANCER APPEAL 80% of callers to the Helpl i ne felt better able . to deal w i th the i i i r enqu ry after speak ng to an

Annual report and fĳ inanc i al statements 2023–2024 | ORCHID CANCER APPEAL

ORCHID CANCER APPEAL | Annual report and fĳ inanc i al statements 2023–2024

‘Despite being the rarest of all c male-speci fi cancers, penile cancer will often cause the most severe physical and psychological side e ects’ ff

Penile cancer

Pen i le cancer w i ll a ff fect 36,000 men globally each year w i th a r i sk of 1 i n 100,000. In the UK i t a ff fects around 760 men each year. In the last few years th i s means that the i nc i dence has i ncreased by just under 10%.

espite being the rarest of all male-speci fĳi c cancers, it will often cause the D most severe physical and psychological side e ff fects because all curative treatment will involve some form of surgery to the penis itself.

D

One of the biggest problems is lack of awareness amongst the public and some healthcare professionals. This can result in inappropriate treatment and therefore a delay in diagnosis increasing the risk of more invasive surgery.

Although men diagnosed with penile cancer are treated at regional specialist centres there remains an inconsistency in support.

Orchid’s 4 Nat i ons Pen i le Cancer Programme is addressing these issues. Many men may feel isolated and face di f i culty in managing the physical and psychological impact of the disease.

Orchid’s website now includes practical information on how to deal with some of these issues, while our telephone counselling service is o ff fering a unique and invaluable service for many men. Over the next year this service will be extended to partners and will include a more in-depth specialist counselling approach where applicable using psychosexual therapy. We have developed a robust referral pathway and protocols.

Orchid is gaining recognition on a European level for the initiatives we are leading and the support that we are o ff fering. For more information on this, see pages 12-14.

Annual report and fĳ inanc i al statements 2023–2024 | ORCHID CANCER APPEAL

ORCHID CANCER APPEAL | Annual report and fĳ inanc i al statements 2023–2024

Patrick’s story

Orchid’s 4 Nations Penile

Cancer Programme

This new programme launched in October 2023 and is led by Urology Cancer Nurse, Sinéad Collins. She has a special interest in this rare cancer and is experienced in the clinical management of this patient group.

The aims of the programme are to raise awareness and the pro fĳi le of penile cancer throughout the four nations by engaging with the general public, primary care and Allied Health Professionals; to work with supranetworks and specialist treatment centres; to create opportunities for sustainable peer support; and to develop a one stop penile cancer information hub.

Plans for Year 2 include presenting to GPs, practice managers and primary care network leads at the ‘Best Practice’ conference in October, addressing urology nurses at the annual British Association of Urology Nurses’ conference in November, and continuing to support patients and healthcare professionals across the four nations.

Urology Cancer Nurse, S i néad Coll i ns jo i ned the programme i n October 2023

4 Nat i ons Pen i le Cancer Programme: Achievements in the year

Attendance at busy Specialists and which is community events such as facilitated by Orchid. This the Belfast Mela and the new group provides a Lambeth Country Show to platform for peer support talk about the risk factors, as well as improving parity signs and symptoms and to by sharing best practice. disseminate information The establishment of an created for the programme. online “Wives, Husbands The availability of posters and Partners” peer support bespoke to each of the four group which is providing nations to display in, for powerful fi rst-hand example, GP practices, testimony as to the reality pharmacies and of the impact of penile community settings. cancer on intimate relationships.

The development of A Four Nations Penile fi rst of its kind written Cancer Conference was information for all Health e held in Manchester to Care Professionals which mark International Penile can be downloaded or Cancer Awareness Day on printed as preferred. September 20th. Oncology Multimedia resources surgeons, Nurse Specialists, and information are now patients and their loved ones attended from across available on the penile cancer hub which the four nations. Together the delegates collated signposts to our virtual ideas and thoughts to and in-person support. create an ideal penile The creation of a Four cancer service. Feedback Nation Nurse Forum from the day was attended by Clinical Nurse overwhelmingly positive.

The creation of a Four Nation Nurse Forum attended by Clinical Nurse

“Two years on I am mentally ten t i mes stronger, ten t i mes more res i l i ent. I have a grasp on l i fe. You have an army of support from Orch i d who are i go ng to back you up and get you through i t the best way you can.”

We are so very grateful to Patr i ck for shar i ng h i s story to ra i se awareness of th i s rare cancer and to help others.

n early 2021, Patrick Meehan was 32, fĳi t, healthy, and busy enjoying his social and I working life when he noticed a rash on his penis.

Like so many others during lockdown, he was unable to arrange a face-to-face appointment with his GP. After a telephone consultation, he was referred to a sexual health clinic where he was given a steroid cream to treat what they thought was an infection. It was not until much later in the year after he developed other symptoms, that Patrick was sent for a biopsy which led to a diagnosis of penile cancer.

When diagnosed, Patrick felt shocked, annoyed and angry. Just before his operation, he called the Orchid Helpline saying, “I don’t know why I am calling you”. Speaking to Orchid Male Cancer Information Nurse Rob Cornes, whom he later described as “his guardian angel”, made Patrick feel safe and supported.

After treatment he felt he needed to talk. Orchid’s Telephone Counselling gave Patrick an understanding of what had happened to him, as well as giving him the building blocks and head space to move forward. Without counselling, he does not think he would have been able to do that.

By being involved with Orchid, he now feels he is part of or a community which really understands his experience, and where he can be totally open and vulnerable: “Two years on I am mentally ten times stronger, ten times more resilient. I have a grasp on life. You have an army of support from Orchid who are going to back you up and get you through it the best way you can.”

a oe ars ‘ea. Tp | e =— 7 al : ¢ ne 4 a = ORCHID CANCER APPEAL | Annual report and fĳ inanc i al statements 2023–2024 Annual report and fĳ inanc i al statements 2023–2024 | ORCHID CANCER APPEAL ; ; tf ~~ ~ o,.) - . a 4 a j i A‘ or ie ee ‘ -ta af : ee L i? j ed : t Li "nano, ) i- & Ye -- ; i ‘ F “ une a al z } 5 Fl i : ‘ ' fi a ‘ ie “3 a a | / F i / _ = aes a = . “= e* : i ; ie — " om : , . @ = : i 1 + 7 : F 4 . J ot 1 ” £ a Hy i ers -am Fi. \ya a; oi ig| E a an Zz 35,840 male cancer lea fl ets, booklets and posters were ordered or requested é wa . 5 Ly ‘ " 4 ae a ele E i tt : : by i nd i v i duals, compan i es, educators, i onals. , a ~

35,840 male cancer lea fl ets, booklets and posters were ordered or requested by i nd i v i duals, compan i es, educators, and healthcare profess i onals. Th i s i s an i ncrease of more than 3,000 compared w i th the prev i ous year.

Annual report and fĳ inanc i al statements 2023–2024 | ORCHID CANCER APPEAL

ORCHID CANCER APPEAL | Annual report and fĳ inanc i al statements 2023–2024

Research The Robert Lane Tissue Bank

rchid was pleased to The a i m of the • has major external collaborations

continue to support the team i s to with prestigious research bodies work of the Robert Lane such as The Institute of Cancer curate a O Tissue Bank during the Research, The Rigshospitalet in bespoke T i ssue year. The Robert Lane Tissue Bank Denmark, University College Bank is led by Professor Dan Berney who London, Memorial Sloan is one of the world’s leading genito- concentrat i ng Kettering Hospital, Indiana urinary pathologists. The Tissue on the three University Hospital, The

Bank carries out translational work male cancers. Cleveland Clinic, and The

which aims to link molecular and So they were Karolinska Institute.

pathological data with clinical del i ghted to • is a valuable source of information trials. The aim of the team is to for students and specialist renew the i r curate a bespoke Tissue Bank researchers wanting to learn more eth i cal concentrating on the three male about male cancers; as well as cancers. They were delighted to approval for being accessible to lay visitors. renew their ethical approval for the the bank for • focuses on samples where

bank in 2024 which will run for further fĳ ive outcome data is available from another fĳi ve years. In summary, it: clinical trials. Advances in years. • holds over 9,000 male-speci fĳi c technology increasingly allow cancer tissue samples to facilitate high quality sequencing and molecular work in these media.

• holds over 9,000 male-speci fĳi c cancer tissue samples to facilitate understanding of prostate, testicular and penile cancers, from the potential causes, through to how they are diagnosed, treated, and possibly prevented.

Professor Dan Berney

Professor Berney is Editor in Chief of H i stopathology , a leading journal in the fĳi eld. He is Past Secretary of the International Society of Urological Pathologists (ISUP), Past Secretary and President of the British Society of Urological Pathologists (BAUP) and Past International Secretary of the British Division of the International Academy of pathologists (BDIAP).

• houses one of the largest collections of penile cancer tissues in Europe, is one of the largest testicular tissue banks in the world and is custodian of the largest series of untreated prostate cancers globally.

• collaborates with research on an international scale, as well as conducting its own pathological and molecular research into penile, prostate, and testicular cancer.

He is the expert pathology lead on testis for the European Association of Urology and helping with their clinical guidance.

works in collaboration with other Orchid funded research projects.

• is committed to the ethical collection, processing, and storage of samples.

He has received from the International Society of Urological Pathology, The Gleason Medal, and

from the British Division of the International Association of Pathology, he received the Cunningham Medal in November 2023.

Professor Berney was co-editor of the 5th edition of the classi fĳi cation of GU-tumours and led on the testis classi fĳi cation for the World Health Organisation and is invited author for .

He has a strong social media presence being one of a select number of uro-pathologists with over 3,000 followers.

He has lectured throughout the world, especially in the USA and also Africa, to improve prostate cancer diagnosis.

He is Visiting Professor at Manipal Medical College in India and was invited to be Visiting Professor at the Cleveland Clinic in Ohio.

Professor Berney has over 320 peer reviewed publications and numerous book chapters on urological pathology. He has an H score of 87 (ie. he has published 87 articles each of which has been cited at least seven times) and his work has been cited over 136,000 times.

Professor Yong-Jie Lu

Professor Yong-Jie Lu whose work Orchid has previously supported is the scienti fĳi c lead on the Robert Lane Tissue Bank Governance Committee and has supervised the day-to-day running/maintenance in the past year, while running his research team on prostate cancer circulating biomarker development.

H i ghl i ghts of the year

12 papers were publ i shed from the group i n the year. Many of these relate to work done on t i ssue from the Robert Lane T i ssue Bank i n the past and donated over 10 years ago yet st i ll i n cl i n i cal use. Professor Berney now has over 320 papers.

Prostate cancer

With Professor G Attard at University College London we continue to work on the STAMPEDE clinical trial which aims to assess new treatment approaches for people a ff fected by high-risk prostate cancer. Ms Larissa Mendez had her fĳi rst abstract accepted on this work to present in Boston in 2025.

Further work continues to be published from the Trans-Atlantic prostate group cohort into early-stage prostate cancer, a longer term follow up is planned as well as a planned project funded by Myriad genetics looking at the use of AI in this cohort to predict outcome.

A collaboration with the Institute of Cancer Research to collect further samples of prostate cancer from recent clinical trials. This supports Orchid work and will focus (among others) on the PACE-B trial which found that men undergoing treatment for prostate cancer could be safely given far less radiotherapy. Tissue has started to be collected and will continue for another two years to 2026.

Testis cancer

The main success of the year continues in the fĳi eld of testis cancer with the publication of the second and third collaboration with Denmark into risk factors to

predict whether testis cancer will come back and whether chemotherapy is needed. These papers will directly a ff fect the decisions on who gets chemotherapy after removal of the cancer in surgery. Professor Berney is lead for the testis International Collaboration on Cancer reporting. This work ensures that pathology reports on testis cancer are standardised worldwide.

With the support of both the Genito-Urinary Pathology Society (GUPS) and the International Society of Urological Pathologists (ISUP), Professor Berney has set up a new group to examine the ‘sex cord stromal tumours’ of the testis. These rare tumours are not well understood, may be malignant and are resistant to treatment. He was the lead on an international meeting in Baltimore in 2024 about these tumours and hopes to make advances in this challenging area.

The logo for this group can be seen below. This group has one paper in press for 2025 and one in preparation and plan to expand this important work for the treatment of rare testis tumours.

Another paper published in January 2025 looks at the rare spermatocytic tumours’ and showed in novel work, which of these usually rare tumours can occasionally behave in an aggressive manner.

Annual report and fĳ inanc i al statements 2023–2024 | ORCHID CANCER APPEAL

ORCHID CANCER APPEAL | Annual report and fĳ inanc i al statements 2023–2024

Research Identifying urine biomarkers for non-invasive prostate cancer surveillance

Character i sat i on of the anaerob i c m i crob i ome and genom i c methylat i on status of prostate cancer pat i ents exper i enc i ng act i ve V i tam i n D and K2 de fĳ ic i ency: prevent i on, r i sk strat ifĳ icat i on, d i agnos i s and treatment potent i al

O

rchid was pleased to the healthcare profession providing R i ght now, support this new a tool for patients’ management. i t’s a ‘ch i cken research project led by Prostate MRI can also be used, or the egg’ Dr Belinda Nedjai who which has been shown to help scenar i o: does is an Associate Professor (Reader) detect prostate cancers that are the presence of specialising in Cancer Biomarkers likely to be aggressive. So, if this these bacter i a and Epigenetics. study shows that we can use bacteria to predict who will develop cause cancer? Summary of the project aggressive or recurring prostate Or does cancer Prostate cancer is one of the most cancer, it could potentially help to allow these common cancers among men but save lives. bacter i a to many people with slow-growing Right now, however, it’s a ‘chicken fl our i sh?

Prostate cancer is one of the most common cancers among men but many people with slow-growing prostate cancer die with it – not of it. A blood test called the prostatespeci fĳi c antigen blood test (PSA) is how patients are screened for prostate cancer. If test results are abnormal, further testing is done with a prostate biopsy, which involves obtaining a small sample of prostate tissue. This process is painful and not always predictive of prostate cancer aggressiveness. A non-invasive solution would greatly bene fĳi t the patients and also

Right now, however, it’s a ‘chicken or the egg’ scenario: does the presence of these bacteria cause cancer? Or does cancer allow these bacteria to fl ourish? In recent results (Phase 1) Dr Nedjai’s work has demonstrated that obligate anaerobes are associated with an increase of PSA and prostate cancer risk. Using a urine test could be another great – and non-invasive way – to detect aggressive prostate cancers. 90% of bacterial species in every human can only grow

without oxygen, ie. obligate anaerobes. Scar tissue after injury or infection can often have reduced blood supply. Bacteria colonising such scarred gastric tissue cause stomach cancer, an idea which was initially ridiculed. Antibacterial treatment now forms the basis of therapy in cancer prevention. Recent research suggests the same may be true for prostate cancer.

Research using genomic methylation studies (these measure switching on and o ff f of genes) has demonstrated chronic

in fl ammation from bacteria a ff fects the methylation status of genes responsible for Vitamin D’s role in controlling bacteria, and prevents Vitamin D working with Vitamin K2 to enhance control of cancer as demonstrated in animal studies.

This research proposal is the fĳi rst to test this issue in humans. Work demonstrating the health bene fĳi ts

of fermenting foods from the ZOE project in King’s College, is making this project more important as Vitamin K2 is produced by food fermentation. At the end of this study, the team hope to not only identify the obligate anaerobes responsible for prostate cancer progression, but they will also understand better the link between obligate anaerobes and vitamin K and D.

This work could pave the way to the design of new clinical trials for cancer prevention (by treating Vitamin D and K de fĳi ciency), early detection (by detecting obligate anaerobes) and treatment (by identifying new prostate cancer progression genes with methylation). The main objective has been to develop prognostic models for individuals using obligate anaerobes and DNA methylation with early lesions, using blood, urine and biopsy material and risk factors to personalise management of screendetected cancers or precancerous lesions to identify those at high-risk, needing more intensive investigations such as MRI scans and molecular studies. Additionally, the aim has to identify those at low-risk, who may bene fĳi t from minimal or even no treatment or further screening.

Dr Nedjai has been exploring three questions over the year. These were:

• Do certain obligate anaerobes drive a speci fĳi c methylation signature?

• Could she and her colleagues identify a non-invasive urine biomarker combining microbiome and DNA methylation to improve the management of patients with indolent cancer on active surveillance?

Can they design a chemo preventive trial to improve the outcome of prostate cancer patients under active surveillance?

A key quest i on for Dr Nedja i and her colleagues: can they des i gn a chemo

prevent i ve tr i al to i mprove the outcome of prostate cancer pat i ents under act i ve surve i llance?

in Cellular and Molecular

Progress made

Physiopathology from the University of Sciences, Pierre et Marie Curie, Paris VI, France, and another Master's degree in Biochemistry with a focus on Immunology and Genetics from the University of Science, Aix Marseille II Luminy, France.

Dr Nedjai and her colleagues have now completed and published a full analysis on the microbiome of urine samples from the PROVENT study. This is a study to see if aspirin with or without vitamin D can delay the progression of prostate cancer in men on active surveillance.

She conducted research for eight years at Imperial College London as post-doctoral researcher and then research Fellow. Her extensive experience spans over 20 years in identifying and validating biomarkers using advanced Next generation sequencing techniques. Her primary research focus is the application of novel quantitative technologies for discovery and validation of DNA methylation biomarkers.

We are delighted to report that this work demonstrates that certain Obligates anaerobes bacteria are associated with high levels of PSA and could perhaps contribute to prostate cancer progression.

January 2025 saw the research published in a paper in Cancers which is an esteemed peer reviewed Journal. A summary of the fĳi ndings will be included in Orchid’s Annual Report for 2024-2025, or can be requested from Orchid.

One of Dr Nedjai’s notable achievements is the development and validation of DNA methylation assays for triaging women infected with papillomavirus, such as the S5 classi fĳi er, which combines DNA methylation of HPV and human genes. This method has been substantially validated in studies worldwide and is considered a gold standard in the fĳi eld of HPV-related cancers. Dr Nedjai is currently involved in numerous studies focussing on the development of screening and triage molecular tools and algorithms to detect HPV related precancer lesions and cancer early.

Dr Belinda Nedjai

Dr Belinda Nedjai is an Associate cancer early. Professor (Reader) specialising in She is dedicated to unravelling Cancer Biomarkers and genetic and epigenetic pathways in Epigenetics. She also serves as the HPV related cancers and working Director of the Molecular on the development of biomarkers Epidemiology Laboratory within for early cancer detection, accurate the Wolfson Institute of Population diagnosis, and e ff fective cancer Health (WIPH). management.

Dr Nedjai earned her Ph.D. in Dr Nedjai's laboratory Functional Genomics from Queen collaborates closely with clinicians, Mary, Bart's, and the London epidemiologists, and statisticians on School of Medicine and Dentistry various clinical trials, exploring in London, UK. Her academic innovative screening, diagnostic, journey includes a Master's degree and treatment approaches.

Annual report and fĳ inanc i al statements 2023–2024 | ORCHID CANCER APPEAL

ORCHID CANCER APPEAL | Annual report and fĳ inanc i al statements 2023–2024

The year ahead

As we head i nto the new inanc i i ll be fĳ al year, work w del i vered i n l i ne w i th the four p i llars i n our organ i sat i onal Strategy 2024 -2028, namely Support, Awareness , Educate and Research . Fundra i s i ng w i ll underp i n everyth i ng we do.

Support

In line with our strategy, we will continue to o ff fer personal support for patients, families and healthcare professionals, promoting how we can help widely to encourage people from across the four nations to access Orchid’s Nurse-led services. Any service development in the coming year will take on board what we hear from patients, their loved ones, and the healthcare professionals working in the fĳi eld.

Our Male Cancer Nurse Specialists will be available fĳi ve days a week to provide information and support to anyone calling Orchid’s Freephone Male Cancer Helpline. Callers to our Helpline may also be signposted to other services, such as Orchid’s telephone counselling service for those diagnosed with penile or testicular cancer, or peer support opportunities.

Plans are in place to use learnings to review our testicular and penile cancer counselling service including the existing protocols, the referral pathway and how its impact is evaluated. Based on feedback from wives and partners of penile cancer patients, we will also be extending this service to them. We will continue to support existing peer support groups, both online and in person. Men continue to tell us there is a lack of support for penile cancer patients, and more is needed. In response, we plan to set up a virtual group which will meet in the evening to be as inclusive as possible, allowing those who work to attend. We will continue to grow the online Wives, Husbands and Partners penile cancer support group in response to need.

The Four Nations Penile Cancer Programme led by Orchid Nurse Sinéad Collins entered its second year in October. During 2024-2025 we will build on the solid foundations and relationships now in place to further raise the pro fĳi le of penile cancer and improve support for anyone who has been a ff fected by the disease, increasing equity across the UK.

Supported by penile cancer patient advocates, Orchid Nurse Rob Cornes, who is a member of the European Association of Urology Patient Advocacy Group and the European Reference Network eUROGEN European Patient Advocacy Group representing both testicular and penile cancer on behalf of Orchid, will continue to work to improve the patient experience for those a ff fected.

Awareness

Knowing that cancers found early are often the easiest to treat, we will raise awareness of male cancers, especially in diverse and vulnerable groups to reduce inequality and to reach those who may not feel able to prioritise their health or who miss mainstream health messaging.

Male Cancer Information Roadshows remain an established part of our community outreach, through which we take information right into the heart of communities, mainly in areas of deprivation. These will be delivered in targeted communities as funding becomes available. We will also continue to o ff fer male cancer talks and presentations to community groups and via our Health at Work programme. As the new year started, talks were being booked in Deaf Clubs to be supported by a British Sign Language interpreter. Bookings were also being made to give talks in Churches with mainly Black African and Black Caribbean congregations in response to Black men’s increased risk of prostate cancer.

An exciting new three-year programme called “Active Participation in Male Cancer Awareness in Prisons” started in August 2024. This is funded by the National Lottery Community Fund and Orchid will deliver talks in prisons across England, attend health days, train residents as Male Cancer Community Champions, and o ff fer support for those diagnosed.

Another innovative development in the year ahead is our new Every Last Drop prostate cancer awareness campaign. This is scheduled to go live in petrol stations in the Brighton area and on the Isle of Man soon after the new year starts. This will be delivered with thanks to sponsorship funding from Astellas, a grant from Takeda and the support of the Isle of Man Anti-Cancer Association.

Digital activity will continue to be important as we use our social media platforms to reach both existing and new audiences with male cancer messaging and information about the support Orchid can o ff fer. Campaigns in the pipeline for delivery in the fĳi rst half of the year include one targeting Deaf people using images and videos of Deaf people and using British Sign Language, one using a young man who was diagnosed with testicular cancer to raise awareness

amongst young men, and another to reach trans women at risk of prostate cancer.

Orchid’s Male Cancer Awareness Week will take place between 15-21 September 2025 with engaging messaging, with International Penile Cancer Awareness Day on 20 September 2025.

Educate

During the year our Nurses will review Orchid information about diagnosis, treatment and care to ensure that it is up to date.

Our Nurses will also continue to promote our resources to, and work with, healthcare professionals to improve the patient journey for those a ff fected by male cancer. We will work to build closer relationships with healthcare professionals such as urologists and pharmacists to disseminate information, as well as with targeted corporate partners to spread male cancer messaging. Furthermore, we will keep working across the four nations to equip people with knowledge about the signs, symptoms, treatment and care options, targeting the most vulnerable and at-risk groups.

Research

Research is vital to understand why men develop prostate, testicular or penile cancer and to improve diagnosis and treatment. There will be two areas of research funded by Orchid grants in the new fĳi nancial year. We are delighted to have committed a grant towards the continuation of the important work led by Professor Dan Berney in the Robert Lane Tissue Bank from 1 October 2024 to 30 September 2025. In addition, work will be continuing for the fĳi rst few months of the year on the research funded by a grant from the Research Innovation Project which is led by Dr Belinda Nedjai.

Annual report and fĳ inanc i al statements 2023–2024 | ORCHID CANCER APPEAL

ORCHID CANCER APPEAL | Annual report and fĳ inanc i al statements 2023–2024

Environmental Policy

At Orchid, we are committed to reducing our carbon footprint and minimising our environmental impact. As part of our ongoing e ff forts, we continuously monitor our activities to align with our Environmental Policy.

One key initiative is optimising how we share resources. Encouraging digital downloads over printed materials will help us reduce paper waste, lower postage costs, and minimise our overall environmental impact, all while ensuring that individuals still have easy access to the vital information and support they need.

Thank you

We are grateful to everyone who contributed towards our work in the last year, as well as to those who will support us in the year ahead. As the year began, a wonderful group of young men in the Sixth Form at Warminster School were busy fundraising ahead of October’s Bournemouth Half Marathon, as were our magni fĳi cent team of runners in the Royal Parks Half Marathon. We are looking forward to supporting more wonderful fundraisers as the year progresses.

Fundraising

Orchid’s work is only possible because of the generosity of our supporters, and we will look after them in every way we can. We will review our supporter care processes to ensure people have an excellent experience whilst fundraising for us. We will continue to o ff fer the best possible support to our corporate partners, the Charitable Trusts and Foundations who give to us, and all the individuals and community groups who support us with donations and fundraise on our behalf.

Our fundraising strategy for the year will be to generate income from diverse income streams at the best possible return on investment to ensure the charity has su f i cient funding in place to deliver our plans for the coming years. We will explore new income generating opportunities in all areas of fundraising. Applications will be submitted to warm Charitable Trusts and Foundations on a rolling basis, carrying out research to identify new potential supporters. We will develop mutually bene fĳi cial partnerships with our corporate supporters to meet their needs as well as Orchid’s. As the current fĳi nancial year has progressed, securing unrestricted income has become increasingly challenging, while operational costs continue to rise. In response, Orchid Trustees have been reviewing all areas of the charity’s work and exploring a range of options to help increase income and reduce expenditure, whilst ensuring the charity remains e ff fective and sustainable.

Annual report and fĳ inanc i al statements 2023–2024 | ORCHID CANCER APPEAL

ORCHID CANCER APPEAL | Annual report and fĳ inanc i al statements 2023–2024

Governance

Orch i d’s a i m i s to prov i de greater knowledge and awareness about male spec ifĳ ic cancers by fund i ng sc i ent ifĳ ic and med i cal research i nto the prevent i on, d i agnos i s and treatment of these d i seases, ra i s i ng awareness, del i ver i ng Nurse-led serv i ces and prov i d i ng i nformat i on about them to people throughout the UK.

Objects, operating context and activities

Objects

The number of people being diagnosed with prostate, testicular or penile cancer in the UK has been increasing. There are now over 58,000 new cases of these cancers each year. Orchid’s aim is to provide greater knowledge and awareness about male speci fĳi c cancers by funding integrated scienti fĳi c and medical research into the prevention, diagnosis and treatment of these diseases, raising awareness, delivering Nurse-led services and providing eye-catching, easy to understand information about them to people throughout the UK, thereby helping to ensure a better quality of life for those a ff fected.

Operating context and activities

Orchid's aim is to o ff fer the best possible care and support for men and their families through awareness and education programmes, to promote better understanding of the signs and symptoms of these cancers, to encourage an early diagnosis and improved outcomes and to ensure the best possible care through our in fl uence at a local and national level. Through funding world class research, our aim is to improve our understanding of male cancers, how they work, possible causes and to identify new treatments and enhance care. Support and information delivered by our

Nurse Specialists and Community Engagement Team enables people interested in or a ff fected by male cancers to have the best possible outcome.

Structure, governance and management

Duly registered as a Charity, Orchid is incorporated as a company, limited by guarantee, and governed by its Memorandum and Articles of Association.

Orchid recognises that an e ff fective Board of Trustees with a balanced composition is essential if the charity is to be e ff fective in achieving its objects, and a new Trustee Recruitment and Training Policy was agreed during the year. Applications from individuals seeking to become a Trustee will be considered as and when appropriate by the Board. Trustees acknowledge the need to increase diversity on the Board and continue to explore the best ways to do this.

A governance audit has been agreed. It will use the template of the Charity Governance Code and the Charity Commission's governance recommendations and will be complemented by a skills audit.

The Board met four times during the year, and most meetings were held virtually during 2023-2024. At the Annual General Meeting, as required by the constitution, one third of the Trustees (or the nearest number thereto) retire from o f i ce in rotation, in order of longevity of appointment and are eligible to be reappointed.

Trustee training and induction

New Trustees are o ff fered an induction programme. All new Trustees receive a copy of Orchid’s governing documentation, the most recent Annual Report, and the Charity Commission’s The essential trustee: what you need to know, what you need to do (CC3). New Trustees are also o ff fered a meeting with the lead programme researchers and a visit to the research programmes. In the absence of in-house provision, or an otherwise formalised programme of training, the Chief Executive advises Trustees of opportunities that will increase their general understanding of voluntary sector, healthcare and/or medical research issues.

Opportunities for ongoing governance training are highlighted in the monthly updates the CEO provides for Trustees. Trustees can elect to attend courses which interest them or which they feel will bene fĳi t them in their role as an Orchid Trustee.

Delegation and decision-

making

The decision-making process operates as follows: At the strategic level, the Board of Trustees regularly reviews Orchid’s direction in the wider context of medical charities, requiring the Chief Executive to identify relevant key issues and present options for its consideration. Due governance

remains a key requirement. The Finance Committee is responsible for the fĳi nancial oversight of the Charity including budgeting, fĳi nancial planning and monitoring as well as fĳi nancial reporting and the creation and monitoring of internal controls and accounting policies. It presents a report to the Board at each of its meetings. As at 30 September 2024, it comprised the Honorary Treasurer, Mr W Cohen, Mr C Osborne and Mr S Harris. At the operational level, the Board delegates the day-to-day running of the Charity to the Chief Executive, requiring him to deliver every aspect of governance, planning and performance in accordance with the agreed strategic direction. The Board is kept appraised of personnel, awareness, research programme and budgetary issues.

Public bene t

The Trustees con fĳi rm that they have complied with the duty in section 17 of the Charities Act 2011 to have due regard to the Charity Commission's general guidance on public bene fĳi t including (PB2 Public Bene fĳi t: Running a Charity).

Key management personnel and remuneration policy Orchid is committed to attracting and retaining talented sta ff f. Sta ff f are kept fully informed of the organisation’s strategy and

objectives, and individual performance is reviewed throughout the year. Learning and development remain a priority. Temporary and volunteer personnel are engaged for speci fĳi c tasks to ensure a balanced approach to managing administration, awareness campaigns, support services and fundraising.

The key management personnel comprise the Trustees and the Chief Executive. Trustees do not receive remuneration. The salary of the Chief Executive is set by the Chairman of the Board of Trustees in consultation with the Finance Committee and Board of Trustees following an annual review of performance. The Charity uses Royal College of Nursing (RCN) bands, NHS pay scales and Charity Salary Surveys for benchmarking salaries of all other members of sta ff f. Annual salary increases for sta ff f are discussed and where applicable approved by the Finance Committee and Board of Trustees.

Given the importance of expert independent peer review in validating applications for new research grants and the veri fĳi cation of outcomes, a Scienti fĳi c Advisory Board provides the Board of Trustees with the necessary degree of objectivity as to the quality, value for money and e f f i ciency of research that the Charity currently funds or may consider funding. Research Programme: Peer Review

Annual report and fĳ inanc i al statements 2023–2024 | ORCHID CANCER APPEAL

ORCHID CANCER APPEAL | Annual report and fĳ inanc i al statements 2023–2024

Internal control and risk

management

Orchid is committed to active management of risk. Risk management is incorporated into governance and management structures, planning processes and all aspects of service delivery. Orchid produces a risk register which identi fĳi es risk and allocates responsibility for managing areas of risk to named individuals. Following Charity Commission recommendations the risk register identi fĳi es risks under the following headings:

Governance and compliance

Operational

Financial

Research

Environmental/external Quality assurance Each identi fĳi ed risk is assessed in terms of likelihood and impact and then weighted giving a gross risk rating. Actions to minimise each risk are identi fĳi ed and responsibility for monitoring these is given to named individuals. The strength of each risk management strategy is given a numeric rating enabling the net risk to be calculated.

The Chief Executive is responsible to the Board for the management and implementation of the risk management strategy and reports to the Board on progress towards mitigating each risk. Risk is reviewed quarterly by sta ff f and not less than annually by the Finance Committee and Board of Trustees. They direct the Chief Executive as to the priorities and action to be taken to mitigate or remove them.

Several other policies, therefore, deal with risk management and risk assessment e.g. Health and Safety Policy, Safeguarding etc. All policies are reviewed annually and updated in line with changes in legislation, regulation and best practice. New policies are introduced as required.

Speci fĳi c risks which, if materialised, would have had a signi fĳi cant impact on the Charity have been identi fĳi ed. These are as follows:

Governance and compliance

Ability to maintain a Board of Trustees with all the skills required to ensure that all aspects of governance are adhered to

Mitigation

An ongoing review of the composition of the Board of Trustees to ensure that all key functions, including medical, legal and fi nancial, are covered by suitably quali fi ed professionals
Training and support for Board of Trustees and Finance Committee
Dedicated specialist resource applied in key areas e.g. health and safety, HR and legal
Ensuring that key management personnel and advisers are of a calibre to ensure that the Charity is aware of and compliant with regulatory and similar requirements

Operational

Attracting, developing and retaining talented sta ff in a competitive employment market

Mitigation

Annual salary review to include benchmarking of compensation and bene fi ts
Sta ff development, training and succession planning programmes
Communication programme to ensure sta ff are involved in the development of and progress towards Orchid’s strategy and annual workplan

Financial

Economic pressures, competition, fundraising regulatory environment and consumer behaviour changes leading to a signi fi cant fall in income

Mitigation

Annual budgeting and ongoing management, reporting and monitoring of fi nancial performance
Diversi cation of income streams
Ongoing consideration of market and consumer trends and regulations including GDPR

Research

Orchid’s Research Programme fails to deliver results

Mitigation

Scrutiny and approval of research funding applications by an expert Scienti fi c Advisory Board
Annual review of progress

Environmental / external

Changes in government policy or budgets, Charity sector regulations, or reform of the NHS or changes to the research environment that negatively impact on Orchid’s work

Mitigation

Key personnel monitor public policy and the regulatory environment on an ongoing basis to ensure potential risks can be proactively managed
Chief Executive and Nurse Specialists attend key events and forums to help shape agenda
Chief Executive and the Board of Trustees routinely scrutinise alignment with, and progress

Quality assurance

Patients, their families, health and social professionals, educators and other interested parties given inaccurate, poor quality information leading to reputational damage

Mitigation

Services developed, delivered and evaluated in line with agreed protocol and standards
Nurse Specialists are members of the Royal College of Nursing (RCN) and the British Association of Urological Nurses (BAUN), and registered with the Nursing and Midwifery Council (NMC)
All information materials and content regularly reviewed and updated
High-quality training for sta ff

Annual report and fĳ inanc i al statements 2023–2024 | ORCHID CANCER APPEAL

ORCHID CANCER APPEAL | Annual report and fĳ inanc i al statements 2023–2024

Financial review

Results for the year

Income for the year ended 30 September 2024 totalled £767,210 (2023: £730,024). After total expenditure of £1,047,335 (2023: £634,721), the year’s activities show a net de fi cit of £280,125 (2023: surplus of £95,303). Total reserves at the end of the year amounted to £357,014 (2023: £637,139).

Reserves policy

Designated reserves are funds that have been earmarked by the Trustees for future expenditure on the objectives of the Charity, and at the end of the year the Trustees had designated £121,808 to help fund the costs of increased organisational capacity with the Charity. Free reserves are distinct from funds that have been earmarked or ‘designated’ for future expenditure on the objectives of the Charity, but for which legal liability has not yet been accepted. They must be maintained at a level which ensure the Charity’s core activity of funding research and awareness during a period of sustained unforeseen di ffi culty and a proportion must be in a readily realisable form. The calculation of the required level of reserves is an integral part of the Charity’s planning, budgeting and forecast cycle. It should take into account:

risks associated with each income and expenditure stream di ff ering from that budgeted
planned activity level
organisational commitments.

The available free reserves net of tangible and intangible fi xed assets are £79,367 (2023: £157,287). It is the Charity’s policy to maintain free reserves of approximately 3–4 months of operating costs. At current levels of expenditure this equates to £155,000–£212,000.

Formal statements

Statement of Trustees’ responsibilities

The Trustees, who are also directors of Orchid Cancer Appeal for the purposes of company law, are responsible for preparing the Trustees’ Report and the fi nancial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice.)

Company law requires Trustees to prepare fi nancial statements for each fi nancial year which give a true and fair view of the state of the a ff airs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these fi nancial statements, the Trustees are required to:

select suitable accounting policies and then apply them consistently;
observe the methods and principles in the Charities SORP;
make judgements and estimates that are reasonable and prudent;
state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the fi nancial statements;
prepare the fi nancial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the fi nancial position of the charitable company and enable them to ensure that the fi nancial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the Charity and fi nancial information included on the Charity’s website. Legislation in the United Kingdom governing the preparation and dissemination of fi nancial statements may di ff er from legislation in other jurisdictions.

Independent Examiner’s information

So far as each of the directors at the time the Trustees’ report is approved is aware:

a) there is no relevant information of which the examiner is unaware; and

b) they have taken all relevant steps they ought to have taken to make themselves aware of any relevant independent examination information and to establish that the examiners are aware of that information.

The examiner, Moore Kingston Smith LLP, has been authorised for appointment in accordance with Section 485 of the Companies Act 2006.

Moore Kingston Smith LLP has indicated its willingness to continue in o ffi ce and in accordance with the provisions of the Companies Act, it is proposed that it will be re-appointed examiner for the ensuing year.

The fi nancial statements have been prepared in accordance with the provisions of the Companies Act 2006 Part 15 relating to small companies, the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (The FRS 102 Charities SORP) and the Memorandum and Articles of Association of the Company.

Signed on behalf of the Trustees

W Cohen, Treasurer 18/06/25

Annual report and fĳ inanc i al statements 2023–2024 | ORCHID CANCER APPEAL

ORCHID CANCER APPEAL | Annual report and fĳ inanc i al statements 2023–2024

Independent Examiner’s Report to the Trustees of Orchid Cancer Appeal

I report to the charity trustees on my examination of the accounts of the Company for the year ended 30 September 2024.

Responsibilities and basis Independent examiner’s I have no concerns and have of report statement come across no other matters in connection with the examination to As the charity’s trustees (and also Since the Company’s gross income which attention should be drawn in its directors for the purposes of exceeded £250,000 your examiner this report in order to enable a proper company law) you are responsible for must be a member of a body listed in understanding of the accounts to the preparation of the accounts in section 145 of the 2011 Act. I con fi rm be reached. accordance with the requirements of the that I am quali fi ed to undertake the Companies Act 2006 (“the 2006 Act”). examination because I am a member of the Association of Chartered Having satis fi ed myself that the NMore Kineton Cady LLP Certi fi ed Accountants which is one of accounts of the Company are not the listed bodies. Adam Fullerton FCA DChA required to be audited under Part 16 of the 2006 Act and are eligible for I have completed my examination. Date: 26 June 2025 independent examination, I report in I con fi rm that no matters have come to For and on behalf of respect of my examination of your my attention in connection with the Moore Kingston Smith LLP charity's accounts as carried out under examination giving me cause to Chartered Accountants section 145 of the Charities Act 2011 believe: 6th Floor, 9 Appold Street, (“the 2011 Act”). In carrying out my 1. accounting records were not kept in London examination I have followed the respect of the Company as required EC2A 2AP Directions given by the Charity by section 386 of the 2006 Act; or Commission under section 145 (5) (b) of the 2011 Act. 2. the accounts do not accord with those records; or 3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or 4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities.

Statement of nancial activities

(incorporating an income and expenditure account) For the year ended 30 September 2024

				Year ended	Year ended
		Unrestricted	Restricted	30 September	30 September
	Note	Total	Total	2024	2023
		£	£	£	£
Income from:
Donations and Legacies	2	467,901	156,644	624,545	567,782
Charitable Activities	4	-	140,344	140,344	160,850
Trading Activities		419	-	419	272
Investment income		1,902	-	1,902	1,120
Total income		470,222	296,988	767,210	730,024
Expenditure on:
Raising funds
Fundraising
(donations and grants)	5	196,759	-	196,759	163,449
Charitable Activities
Education and Awareness	5	332,846	284,001	616,847	420,021
Research	5	22,694	211,035	233,729	51,251
Total expenditure		552,299	495,036	1,047,335	634,721
Net income / (expenditure) and
net movement in funds	5,6	(82,077)	(198,048)	(280,125)	95,303
Reconciliation of funds
Total funds brought forward		298,601	338,538	637,139	541,836
Total funds carried forward		216,524	140,490	357,014	637,139

All of the above results are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in Note 14 to the fi nancial statements.

Annual report and fĳ inanc i al statements 2023–2024 | ORCHID CANCER APPEAL

ORCHID CANCER APPEAL | Annual report and fĳ inanc i al statements 2023–2024

Balance sheet

As at 30 September 2024

			30 September		30 September
			2024		2023
Note	Note	£	£	£	£
Fixed Assets
Tangible Assets 10	Tangible Assets 10		3,225		3,340
Intangiblefixed assets 11	xed assets 11		12,125		16,166
Current Assets
Cash at bank and in hand	Cash at bank and in hand	526,386		630,903
Debtors 12	Debtors 12	157,187		67,957
		683,573		698,860
CREDITORS
Amounts due within one year 13	Amounts due within one year 13	(341,909)		(81,227)
Net Current Assets			341,664		617,633
Total Assets less Current Liabilities	14		357,014		637,139
NET ASSETS			357,014		637,139
Represented by:15	15
General Unrestricted Funds	General Unrestricted Funds	94,717		176,793
Designated Funds	Designated Funds	121,808		121,808
			216,525		298,601
Restricted funds	Restricted funds		140,489		338,538
			357,014		637,139

The company is limited by guarantee.

For the year ending 30 September 2024 the charitable company was entitled to exemption from statutory audit under Section 477 of the Companies Act 2006 relating to small companies.

Statement of cash ows

For the year ended 30 September 2024

	2024		2023
	£	£	£	£
Cashflows from operating activities:
Net (expenditure)/income for the year	(280,125)		95,303
Adjustments for:
Depreciation charges	5,655		5,338
Interest	(1,902)		(1,120)
Decrease / (increase) in debtors	(89,230)		40,849
(Decrease) / increase in creditors	260,682		(89,282)
Net cash (used in)/provided by
operating activities	(104,920)		51,088
Cashflows from investing activities:
Interest	1,902		1,120
Purchase offixed asset	(1,499)		(11,749)
Net cash (used in) investing activities		403		(10,629)
Change in cash and cash equivalents in the year		(104,517)		40,459
Cash and cash equivalents at the beginning of the year		630,903		590,444
Cash and cash equivalents at the end of the year		526,386		630,903
Analysis of cash and cash equivalents
Cash at bank and in hand		526,386		630,903
		526,386		630,903

No notice from Trustees requiring an audit has been deposited under Section 476 of the Companies Act 2006.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and for the preparation of accounts.

The fi nancial statements have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

The fi nancial statements were approved by the Board and authorised for issue on 18/06/25 and signed on its behalf by:

----- Start of picture text -----
Nw
----- End of picture text -----

Mr W Cohen Company number 3963360

Annual report and fĳ inanc i al statements 2023–2024 | ORCHID CANCER APPEAL

ORCHID CANCER APPEAL | Annual report and fĳ inanc i al statements 2023–2024

Notes to the nancial statements

1. Accounting policies

For the year ended 30 September 2024

Basis of Preparation

These fi nancial statements have been prepared under the historical cost convention and in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102). The Charity is a public bene fi t entity for the purposes of FRS 102 and therefore has also prepared the fi nancial statements in accordance with the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (The FRS 102 Charities SORP), the Companies Act 2006 and the Charities Act 2011.

Going Concern

The trustees have assessed whether the use of the going concern assumption is appropriate in preparing these fi nancial statements. The trustees have made this assessment in respect to a period of one year from the date of approval of these fi nancial statements. In particular the trustees have considered the charities forecasts and projections and have taken account of pressures on donation income. After making enquiries the trustees have concluded there is a degree of uncertainty around donation income for 2024/25 however that there is a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. The charity therefore continues to adopt the going concern basis in preparing its fi nancial statements.

The trustees con fi rm that there are no material uncertainties about the

ability of the charity to continue as a going concern. The charity, therefore, continues to adopt the going concern basis in preparing its fi nancial statements.

Funds Accounting

General funds are unrestricted funds available for use at the discretion of the Trustees in furtherance of the general activities of the Charity and which have not been designated for other purposes.

Functional Currency

The functional currency is considered to be in pounds sterling because that is the currency of the primary economic environment in which the charity operates. The fi nancial statements are also presented in pounds sterling, rounded to the nearest £1.

Designated funds comprise funds which have been set aside at the discretion of the Trustees for speci fi c purposes.

Restricted funds are funds subject to speci fi c restrictions imposed by donors or by the nature of the appeal.

Taxation

Income

The Charity has su ff ered no tax charge as it is not subject to UK Corporation tax on its charitable activities.

Income becoming available to the Charity is recognised when there is entitlement to the income, probability of receipt and amounts can be measured reliably as per FRS102 SORP.

Depreciation

Depreciation is provided at the following annual rates so as to write o ff the cost of each asset over its useful life. Assets with a purchase consideration in excess of £1,000 are capitalised.

Gifts in kind are valued and brought in as income and the appropriate expenditure, when the items are used/distributed. The values attributable to gifts in kind are an estimate of the gross value to the organisation, where quanti fi able. Where this intangible income relates to project activities, it is included as an activity in furtherance of the Charity's objects.

Computer and O ffi ce Equipment - 33 1/3% on written down value.

Intangible xed assets

Expenditure

Intangible fi xed assets are included in Cost of raising funds includes costs the balance sheet at original cost less associated with the fund-raising events accumulated amortisation. in furtherance of the Charity’s objects.

the balance sheet at original cost less accumulated amortisation. Amortisation is provided on a straight line basis calculated to write down the cost of all intangible assets to their estimated residual values over the

Charitable expenditure includes costs associated with particular activities in furtherance of the Charity’s objects.

number of years of expected use. Assets

Governance costs are those incurred in connection with the management of Website - 20% on straight line value the Charity’s assets, organisational

administration, and compliance with constitutional and statutory requirements and are included within support costs.

Charitable expenditure comprises direct expenditure including direct sta ff costs attributable to the activity. Support costs which cannot be directly attributed to an activity have been allocated to activities on a basis consistent with use of the resources.

Grants payable are charged when the o ff er is conveyed to the recipient except in those cases where the o ff er is conditional, such grants being recognised as expenditure when the conditions attaching are ful fi lled. Grants o ff ered subject to conditions which have not been met at the balance sheet date are noted as a commitment, but not accrued as expenditure.

Financial Instruments

The charitable company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ of FRS 102 to all of its fi nancial instruments. Financial instruments are recognised in the Charity's balance sheet when the Charity becomes party to the contractual provisions of the instrument. Financial assets and liabilities are o ff set, with the net amounts presented in the fi nancial statements, when there is a legally enforceable right to set o ff the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously. With the exceptions of prepayments, deferred income and amounts owed to or from HMRC. All

other debtor and creditor balances are considered to be basic fi nancial instruments under FRS 102.

Debtors

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the e ff ective interest method, less any impairment.

Cash and Cash equivalents

Cash and cash equivalents in the balance sheet comprise cash at banks and in hand and term deposits with an original maturity date of three months or less. For the purpose of the statement of cash fl ows, cash and cash equivalents consist of cash and cash equivalents as de fi ned above.

Creditors

Short term trade creditors are measured at the transaction price. Other fi nancial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the e ff ective interest method. Deferred income represents grants, contract funding and training fees relating to future periods.

Pension Scheme

The Charity operates a de ned

contribution stakeholder pension scheme. The amount charged to the statement of fi nancial activities in respect of pension costs is the Charity's contributions payable in the year. The assets of the scheme are held separately from the Charity. There was no outstanding liability owed to the scheme at the end of the current or prior years.

Employee Bene fi ts

The cost of short-term employee bene fi ts are recognised as a liability and an expense. The cost of any material unused holiday entitlement is recognised in the period in which the employee’s services are received.

Critical accounting estimates and areas of judgement

In the view of the Trustees in applying the accounting policies adopted, no judgements were required that have signi fi cant e ff ect on the amounts recognised in the fi nancial statements nor do any estimates or assumptions carry a signi fi cant risk of material adjustment in the next fi nancial year.

Annual report and fĳ inanc i al statements 2023–2024 | ORCHID CANCER APPEAL

ORCHID CANCER APPEAL | Annual report and fĳ inanc i al statements 2023–2024

2. Donations

Current year
Individuals
Legacies
Corporates
Trusts and Foundations
Fundraising Events
Total
Prior year
Individuals
Legacies
Corporates
Trusts and Foundations
Fundraising Events
Total

Year ended
Year ended
30 September 2024
30 September 2023
Restricted
Unrestricted
Total
Total
£
£
£
£
1,360
155,961
157,321
58,012
-
-
-
19,147
-
91,226
91,226
76,601
155,284
49,850
205,134
264,628
-
170,864
170,864
149,394
156,644
467,901
624,545
567,782
Year ended
30 September 2023
Restricted
Unrestricted
Total
£
£
£
500
57,512
58,012
-
19,147
19,147
-
76,601
76,601
256,650
7,978
264,628
-
149,394
149,394
257,150
310,632
567,782

3. Fundraising events

Current year
Cycling events
Running events
Third party organised events
Trek
Other
Total
Prior year
Cycling events
Running events
Third party organised events
Trek
Other
Total

Year ended
Year ended
30 September 2024
30 September 2023
Restricted
Unrestricted
Total
Total
£
£
£
£
-
9,253
9,253
2,296
-
57,014
57,014
68,852
-
99,324
99,324
63,886
-
-
-
92
-
5,273
5,273
14,268
-
170,864
170,864
149,394
Year ended
30 September 2023
Restricted
Unrestricted
Total
£
£
£
-
2,296
2,296
-
68,852
68,852
-
63,886
63,886
-
92
92
14,268
14,268
-
149,394
149,394

4. Charitable activities

Current year National Lottery Community Fund Total Prior year National Lottery Community Fund Total	Year ended Year ended 30 September 2024 30 September 2023 Restricted Unrestricted Total Total £ £ £ £ 140,344 - 140,344 160,850 140,344 - 140,344 160,850 Year ended 30 September 2023 Restricted Unrestricted Total £ £ £ 160,850 - 160,850 160,850 - 160,850

Annual report and fĳ inanc i al statements 2023–2024 | ORCHID CANCER APPEAL

ORCHID CANCER APPEAL | Annual report and fĳ inanc i al statements 2023–2024

7. Net expenditure for the period

5. Total expenditure

Cost of
Education and
raising funds
Awareness
£
£
Grants
-
-
Stafcosts
91,218
192,408
Fundraising expenses
60,767
-
Information materials
-
293,692
Direct costs
-
27,196
151,985
513,296
Support costs
Depreciation
1,590
3,734
Other
34,130
80,121
Governance - stafcosts
6,551
13,820
Governance -
independent examiners
2,503
5,876
44,774
103,551
Total expenditure
196,759
616,847
Prior year
163,449
420,021

Year ended
Year ended
30 September 2024
30 September 2023
Research
Total
Total
£
£
£
205,428
205,428
18,519
18,983
302,609
264,654
-
60,767
39,663
-
293,692
126,256
-
27,196
33,511
224,411
889,692
482,603
331
5,655
5,338
7,103
121,354
117,930
1,363
21,734
22,099
521
8,900
6,751
9,318
157,643
152,118
233,729
1,047,335
634,721
51,251
634,721

6. Grants awarded

6. Grants awarded
	Year ended	Year ended
	30 September 2024	30 September 2023
	Total	Total
	£	£
Grant commitments brought forward	35,646	126,617
Institutional grants for medical research awarded during year/period
– Orchid Study and Travel Awards (2024: 2 individuals, 2023: 2 individuals)	1,128	1,000
– Barts and London School of Medicine	54,398	35,646
– Write of	149,902	(18,128)
Payments made during period/year	(4,182)	(108,489)
Grant commitments carried forward	236,892	36,646
Payable less than one year	236,892	36,646
Payable two tofve years	-	-

	Year ended	Year ended
This is stated after charging:	30 September 2024	30 September 2023
	Total	Total
	£	£
Depreciation	1,613	1,297
Independent examiners’ remuneration:
Independent examination	5,700	5,435
Trustees’ remuneration	-	-

8. Sta ff costs and numbers

8. Staf costs and numbers
	Year ended	Year ended
Staffcosts were as follows:	30 September 2024	30 September 2023
	Total	Total
	£	£
Salaries and wages	269,204	235,955
Social security costs	22,772	18,666
Pension contributions	3,307	2,122
	295,283	256,743
Consultant costs	29,060	30,010
Total cost	324,343	286,753

During the year ended 30 September 2024, one employee earned more than £60,000 (Year to 30 September 2023: 1). The pension contribution paid in respect of this employee totalled £Nil (2023: £Nil)

The key management personnel of the charity comprise the trustees and the chief executive. The charity trustees do not receive remuneration.

The total remuneration of the chief executive was £86,324 (year ended 30 September 2023: £83,579).

The number of employees whose emoluments amounted to over £60,000 in the year (exclusive of employer pensions and employer National Insurance contributions) was as follows:

2024 2023 No. No. £70,000–£79,999 1 1

The average number of employees during the year was 7.4 (2023: 7.4)

The average number of employees during the year on a headcount basis was as follows:

2024 2023 No. No. Fundraising 1.7 1.7 Education and Awareness 5.4 5.4 Grant support 0.3 0.3 Overall average 7.4 7.4

Annual report and fĳ inanc i al statements 2023–2024 | ORCHID CANCER APPEAL

ORCHID CANCER APPEAL | Annual report and fĳ inanc i al statements 2023–2024

9. Taxation

The charitable company is exempt from corporation tax as all its income is charitable and is applied for charitable purposes.

10. Tangible fi xed assets

10. Tangiblefxed assets
	Computer and	30 September
	office equipment	2024
	Total	Total
	£	£
Cost
At the start of the period	10,924	10,924
Additions	1,499	1,499
At the end of the period	12,423	12,423
Depreciation
At the start of the period	7,584	7,584
Charge for Period	1,614	1,614
At the end of the period	9,198	9,198
Net book value
At the end of the period	3,225	3,225
At the start of the period	3,341	3,341

11. Intangible fi xed assets

11. Intangiblefxed assets
	Website	30 September
	development	2024
	Total	Total
	£	£
Cost
At the start of the period	20,208	20,208
Additions	-	-
At the end of the period	20,208	20,208
Amortisation
At the start of the period	4,042	4,042
Charge for Period	4,041	4,041
At the end of the period	8,083	8,083
Net book value
At the end of the period	12,125	12,125
At the start of the period	16,166	16,166

12. Debtors

12. Debtors
Prepayments Other debtors and accrued income	Year ended Year ended 30 September 2024 30 September 2023 Total Total £ £ 69,476 7,439 87,711 60,518 157,187 67,957
Grants Payable Trade and Other Creditors Accruals 13. Creditors: amounts due within one year	Year ended Year ended 30 September 2024 30 September 2023 Total Total £ £ 236,892 35,646 62,976 11,424 42,041 - 341,909 47,070
14. Movements in funds Brought forward £ Unrestricted General 176,793 Designated – Development 121,808 Total unrestricted 298,601 Restricted Counselling - The National Lottery Community Fund: – Overcoming the Barriers 29,030 The National Lottery Community Fund: – Active Participation in Male Cancer Awareness in Prisons - The Innovation Research Project 156,137 Penile Cancer Peer Support 1,565 Education and Awareness 4,000 Student Study and Travel Scholarships 3,729 Roadshows - Robert Lane Tissue Bank 13,054 Nurse Led Services 2,000 Four nations penile cancer programme 129,023 Total restricted 338,538 Total funds 637,139	Income Expenditure Carried forward £ £ £ 470,222 (552,299) 94,716 - - 121,808 470,222 (552,299) 216,524 10,000 (5,500) 4,500 81,629 (110,659) - 58,715 (7,630) - 500 (156,637) - 2,484 (3,244) 805 22,500 (25,500) 1,000 - (1,000) 2,729 50,160 (49,300) 860 49,500 (54,398) 8,156 31,500 (17,000) 16,500 - (69,668) 59,355 296,988 (495,036) 140,490 767,210 (1,047,335) 357,014

Annual report and fĳ inanc i al statements 2023–2024 | ORCHID CANCER APPEAL

ORCHID CANCER APPEAL | Annual report and fĳ inanc i al statements 2023–2024

14. Movements in funds (continued)

Prior year movements in funds
Brought forward
£
Unrestricted
General
175,208
Designated – Development
121,808
Total unrestricted
297,016
Restricted
The National Lottery Community Fund
- RC England-wide
32,445
Male Cancer Nurse Information Specialist
- other funders
8,252
The Innovation Research Project
92,800
Penile Cancer Peer Support
-
Education and Awareness
5,000
Student Study and Travel Scholarships
6,729
Roadshows
2,860
Robert Lane Tissue Bank
-
Nurse Led Services
-
Four nations penile cancer programme
-
Total restricted
244,820
Total funds
541,836

Income
Expenditure
Carried forward
£
£
£
312,024
(310,439)
176,793
-
-
-
312,024
(310,439)
298,601
166,673
(158,322)
29,030
12,100
(16,752)
0
68,700
(7,320)
156,137
8,500
(7,500)
1,565
58,950
(30,295)
4,000
-
(2,000)
3,729
42,871
(38,871)
0
48,700
(35,646)
13,054
2,000
-
2,000
130,000
(977)
129,023
418,000
(324,282)
338,538
730,024
(634,721)
637,139

15. Analysis of net assets between funds

Unrestricted funds £ Fixed Assets 3,225 Current Assets 555,207 Creditors due within one year (341,908) Net assets at 30 September 2024 216,524 Prior year analysis of net assets between funds Unrestricted funds £ Fixed Assets 3,340 Current Assets 376,490 Creditors due within one year (81,229) Net assets at 30 September 2023 298,601	Restricted Total funds at funds 30 September 2024 £ £ - 3,225 140,490 695,697 - (341,908) 140,490 357,014 Restricted Total funds at funds 30 September 2023 £ £ - 3,340 338,538 715,028 - (81,229) 338,538 637,139

16. Related party transactions

Aggregate donations of £50,000 were received from trustees in the year ended 30 September 2024. (Year to 30 September 2023: £500).

General funds are unrestricted funds available for use at the Trustees’ discretion in furtherance of the general activities of the charity and which have not been designated for other purpose

Designated Development funds represent monies set aside at the Trustees’ discretion to be used to help fund the costs related to increasing the organisational capacity of the charity.

17. Financial commitments

For the year ended 30 September 2024, the charity was committed to making the following future payments under non cancellable operating leases.

	Year ended	Year ended
	30 September 2024	30 September 2023
	Total	Total
Land and buildings	£	£
Expiring within one year	15,637	15,637
Expiring within two tofve years	-	-
	15,637	15,637

18. Capital commitments

At the year ended 30 September 2024, the charity had no capital commitments.

ORCHID FIGHTING MALE CANCER

2024-09-30-accounts

Orchid: here for those who need us “4 most.

ORCHID CANCER APPEAL inanc i al Annual report and fĳ statements 2023–2024

Board of Trustees

Mr D Badenoch

Chief Executive

Independent Examiner

Accountants

Legal advisors

Bankers

Welcome from Col i n Osborne MBE, Honorary Pres i dent

Orch i d – here today, g i v i ng hope for the future

A

The year in review

T

Positive feedback, unique service

Mark of Excellence

On the road again

Double the reach

Focusing on facts

Helpline increase

Barriers overcome

HMP Orchid

Four nations, one programme

National conference

Diverse communities

Download here

On the European stage

Forecourt and foyer

Thank you

Fundraising

O

Pedal for Pride, Fight for Life!

Orchid’s collaborative role in European urological initiatives

A

European Association of Urology EAU Testicular Cancer Guidelines panel

EAU Patient Advocacy Group

European Assoc i at i on of Urology

Thank you to our incredible Orchid volunteers!

European Reference Network for Rare Urogenital Diseases ERN (eUROGEN)

What this collaboration means for patients

European Reference Network for Rare Urogen i tal D i seases ERN (eUROGEN)

V

O

Orchid wins top UK health award

On the road with Orchid’s Male Cancer Roadshows

Social media: a vital tool for changing lives

Warn-a-Brother

Overcoming I the Barriers to Engaging with Prostate Cancer

Prostate cancer

National Prostate Cancer Awareness Conference

Sally’s story

Testicular cancer

T

The battle begins

A second battle

A third fi ght

Turning pain into purpose: Coaching and giving back

Penile cancer

D

Patrick’s story

Orchid’s 4 Nations Penile

Cancer Programme

4 Nat i ons Pen i le Cancer Programme: Achievements in the year

Research The Robert Lane Tissue Bank

Professor Dan Berney

Professor Yong-Jie Lu

H i ghl i ghts of the year

Prostate cancer

Testis cancer

Research Identifying urine biomarkers for non-invasive prostate cancer surveillance

O

Progress made

Dr Belinda Nedjai

The year ahead

Support

Awareness

Educate

Research

Environmental Policy